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Abstract  
 
 
Background: Little is known about the mechanisms, clinical characteristics, natural history and 
outcomes of cardiomyopathy amongst Africans. Familial aggregation of cardiomyopathy has not 
been studied systematically in an African setting. Further, it is not clear whether the various 
phenotypic expressions of cardiomyopathy represent disparate clinical entities, or whether they are 
merely different forms of the same disease manifested differently in different circumstances.  
Methods: Two cohorts of patients with cardiomyopathy were utilised for this study: (1) patients 
with cardiomyopathy seen at the specialist cardiomyopathy clinic at Groote Schuur Hospital, Cape 
Town between February 1, 1996 and December 31, 2009; and (2) a group of hypertrophic 
cardiomyopathy (HCM) patients and first degree relatives seen in a specialist cardiogenetic clinic at 
Tygerberg Hospital, who underwent cardiovascular magnetic resonance (CMR) imaging at Groote 
Schuur Hospital. 
Results: 29 out of 109 unrelated cases with dilated cardiomyopathy (DCM) had familial disease, 
and had a significantly younger mean age of onset of cardiomyopathy than non-familial cases. Two 
of the 29 patients with familial DCM had at least one relative who was diagnosed with peripartum 
cardiomyopathy (PPCM). Pedigree analysis of the 29 families was consistent with autosomal 
dominant (AD) inheritance in 72.4%, autosomal recessive inheritance in 17.2% and X-linked 
recessive inheritance in 10.4%. Cardiac chambers were significantly more dilated with poorer left 
ventricular (LV) systolic function in idiopathic than familial cases. The mortality rate of 40% after a 
median follow-up of 5 years was, however, similar in both groups. The presence of New York 
Heart Association functional class III and IV symptoms was an independent predictor of mortality, 
whilst heart transplantation was an independent predictor of survival in both groups. Digoxin use 
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without serum monitoring was a significant predictor of mortality in idiopathic DCM. We present 
the longest follow-up study of PPCM in Africans, showing (1) a case fatality rate of 16.7% over a 
median of 4.3 years in patients on modern medical therapy; (2) PPCM is associated with adverse 
outcomes; (3) chronic heart failure occurs in 80% of patients studied, and with virtually no 
normalisation of LV dysfunction; and (4) that persistence of symptoms of heart failure are the 
strongest predictor of death in patients with PPCM. We compared the time of onset of symptoms, 
clinical profile and outcome of patients with hypertensive heart failure of pregnancy (HHFP) and 
PPCM and found onset of symptoms to be postpartum in all PPCM patients and antepartum in 85% 
of HHFP. PPCM was associated with more severe complications and a higher rate of mortality than 
HHFP.   
The clinical presentation of HCM was similar to that reported in other studies. The South African 
founder mutations that cause HCM were not found in the 42 probands studied and 29% of those 
tested for mutations in 15 genes had disease causing mutations in MYH7 and MYBPC3. Overall 
survival of HCM was 74% at 10 years, which was similar to the general South African population. 
The independent predictor of mortality was New York Heart Association (NYHA) functional class 
at last visit (P=0.026), but not by presence of a disease-causing mutation (P=0.474). Finally, we 
investigated the correlation between genotype and cardiovascular magnetic resonance (CMR) 
phenotype in HCM patients with the 3 founder South African mutations and found variable 
phenotypic expression associated with the different genotypes.  
Conclusions: Familial DCM affects at least a quarter of African patients with DCM, presents at a 
young age, is associated with PPCM, and follows an AD pattern of inheritance in the majority of 
families. Patients with idiopathic DCM have greater cardiac dysfunction than those with familial 
disease, but mortality remains similarly high in both groups. Digoxin use without drug-level 
monitoring may be associated with increased mortality in idiopathic DCM. Persistent symptoms 
predict poor outcomes in PPCM. There are significant differences in the time of onset of heart 
failure, clinical and echocardiographic features, and outcome of HHFP compared to PPCM, 
indicating that the presence of hypertension in pregnancy-associated heart failure may not fit the 
case definition of idiopathic PPCM. Comprehensive genetic screening was associated with a 29% 
yield of causal genetic mutations in South African HCM cases, all in MYH7 and MBPC3 genes. 
NYHA functional class at last visit, but not presence of a disease-causing mutation, was an 
independent predictor of mortality. Multiparametric CMR demonstrated variable phenotypic 
expression in HCM mutation carriers with differing genotypes. 
 
Keywords  
Cardiomyopathy, sub-Saharan Africa, South Africa, heart failure, dilated cardiomyopathy, familial 
cardiomyopathy, hypertrophic cardiomyopathy, peripartum cardiomyopathy, cardiovascular 
magnetic resonance, echocardiography 
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Chapter 1 
 
 
 Introduction and study rationale 
 
 
 1.1     Historical perspectives, evolving concepts and definition of cardiomyopathy 
Cardiomyopathies are primary disorders of heart muscle associated with left ventricular (LV) 
dysfunction and development of heart failure.1 The very first description of dilated cardiomyopathy 
was probably provided by Gillanders in 1951.  In 1980, the World Health Organization (WHO) 
defined cardiomyopathies as "heart muscle diseases of unknown cause," to distinguish 
cardiomyopathy from cardiac dysfunction due to known entities such as hypertension, ischaemic 
heart disease, valvular disease, pericardial disease or congenital heart disease.2 However, in clinical 
practice, the term "cardiomyopathy" has also often been applied incorrectly to diseases of known 
cause (e.g. ‘ischaemic cardiomyopathy’ and ‘hypertensive cardiomyopathy’). Consequently, the 
1995 WHO/International Society and Federation of Cardiology (ISFC) Task Force on the 
Definition and Classification of the Cardiomyopathies expanded the classification to include all 
diseases affecting heart muscle and to consider aetiology as well as the dominant pathophysiology.3 
In this 1995 classification, the cardiomyopathies were defined as "diseases of the myocardium 
associated with cardiac dysfunction." They were classified according to anatomy and 
pathophysiology into the following types, each of which has multiple different causes: (a) dilated 
cardiomyopathy (DCM); (b) hypertrophic cardiomyopathy (HCM); (c) restrictive cardiomyopathy 
(RCM); (4) arrhythmogenic right ventricular cardiomyopathy (ARVC); and (5) unclassified 
cardiomyopathies.3 
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In 2006, the American Heart Association (AHA) published a scientific statement that proposed a 
contemporary definition and classification of the cardiomyopathies.4 The AHA expert consensus 
panel proposed the following definition: "Cardiomyopathies are a heterogeneous group of diseases 
of the myocardium associated with mechanical and/or electrical dysfunction that usually (but not 
invariably) exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of 
causes that frequently are genetic. Cardiomyopathies either are confined to the heart or are part of a 
generalised systemic disorders, often leading to cardiovascular death or progressive heart failure-
related disability."4 In this new scheme, cardiomyopathies were categorised into two groups: (a) 
primary cardiomyopathies, which may be genetic, mixed (genetic or non-genetic), or acquired; and 
(b) secondary cardiomyopathies, which are accompanied by other organ/system involvement (Table 
1.1). The AHA definition and classification were not intended to provide methodologies for clinical 
diagnosis, but were rather a scientific scheme that aimed to aid in the understanding of this complex 
group of disorders. The main departure of the proposed AHA Scientific Statement definition from 
previous classifications was the inclusion of the ion channelopathies as primary cardiomyopathies, 
despite the absence of gross structural abnormalities of cardiac muscle. 
 
In 2007, the European Society of Cardiology's (ESC) working group on myocardial and pericardial 
diseases presented an update to the WHO/ISFC classification in which cardiomyopathy was defined 
as: "A myocardial disorder in which the heart muscle is structurally and functionally abnormal in 
the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease 
sufficient to explain the observed myocardial abnormality." This ESC classification was a 
significant departure from the WHO/ISFC classification in that the distinction between 
familial/genetic and non-familial/non-genetic causes of LV dysfunction were emphasised, and heart 
disease secondary to hypertension, ischaemic heart disease, pericardial, valvular, and congenital 
disorders were not included.5 Importantly, in the ESC classification, unlike in the AHA 
classification, channelopathies were excluded as well (Figure 1.1 and Table 1.2).  
 
Table 1.1. The AHA classification of the cardiomyopathies 
Primary 
cardiomyopathies 
Genetic HCM, ARVC, LVNC, conduction defects, mitochondrial 
myopathies, ion channel disorders 
Mixed DCM, RCM 
Acquired Inflammatory, Takotsubo, peripartum, tachycardia-induced, 
infants of diabetic mothers 
Secondary 
cardiomyopathies 
Infiltrative Amyloidosis, Gaucher’s, Hurler’s, Hunter’s 
Storage Anderson-Fabry’s, glycogen storage diseases, Niemann-Pick 
disease, haemochromatosis 
Toxicity Drugs, heavy metals 
Endomyocardial Endomyocardial fibrosis, Loeffler’s endocarditis 
Inflammatory Sarcoidosis 
Endocrine Diabetes, hyperthyroidism, hypothyroidism, hyperparathyroidism, 
phaeochromocytoma, acromegaly 
Cardiofacial Noonan’s, lentoginosis 
Neuromuscular Friedrich’s ataxia, Duchenne-Becker muscular dystrophy, 
myotonic dystrophy 
Nutritional Beriberi, scurvy, selenium deficiency 
Autoimmune RA, SLE, SSc, dermatomyositis 
Consequence of 
therapy 
Anthracyclines, radiation, cyclophosphamide 
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, 
hypertrophic cardiomyopathy; LVNC, left ventricular non-compaction; RA, rheumatoid arthritis;  
RCM, restrictive cardiomyopathy; SLE, systemic lupus erythematosus; SSc, systemic sclerosis 
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Figure 1.1. European Working Group on Myocardial and Pericardial Diseases ESC 
classification of the cardiomyopathies 
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, 
hypertrophic cardiomyopathy; RCM, restrictive cardiomyopathy 
From Elliott P, et al. Classification of the cardiomyopathies: a position statement from the European 
Society of Cardiology Working Group on Myocardial and Pericardial diseases. Eur Heart J 
2008;29:270-276.  
 
In 2013, the World Heart Federation endorsed the MOGE(S) classification 6,7 which was developed 
from the need to describe cardiomyopathies by integration of a morphofunctional phenotype-based 
description with information regarding extracardiac organ involvement and clinical (pattern of 
inheritance) and molecular (disease gene and mutation) genetics in familial disease. The MOGE(S) 
classification also aimed to describe sporadic cardiomyopathies, and specify their etiology when 
known or unknown (Table 1.3).  
 
 
 
Table 1.2. The ESC classification of cardiomyopathies by cause 
 
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, 
hypertrophic cardiomyopathy; RCM, restrictive cardiomyopathy 
From Elliott P, et al. Classification of the cardiomyopathies: a position statement from the European 
Society of Cardiology Working Group on Myocardial and Pericardial diseases. Eur Heart J 
2008;29:270-276. 
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Table 1.3. The MOGE(S) classification of cardiomyopathies 
 
From Arbustini E, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of 
cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol 2013;62:2046-2072. 
 
In 2014, the ESC published guidelines on the diagnosis and management of hypertrophic 
cardiomyopathy.8 These guidelines comprise a comprehensive review of the literature on HCM, the 
evolving understanding of the disease, current concepts, diagnosis of HCM and HCM phenocopies 
and evidence based strategies for risk stratification and management of the condition. HCM is 
defined by the presence of increased left ventricular (LV) wall thickness that is not solely explained 
by abnormal loading conditions (Figure 1.2).  
 
 
 
Figure 1.2. The complex aetiology of left ventricular hypertrophy 
From Elliot P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic 
Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-2779. 
 
 
In 1994, an International Task Force proposed criteria for the clinical diagnosis of ARVC that 
facilitated recognition and interpretation of the frequently nonspecific clinical features of ARVC, 
resulting in confirmatory clinical diagnosis in index cases through exclusion of phenocopies and 
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provision of a standard on which clinical research and genetic studies could be based.9 Structural, 
histological, electrocardiographic, arrhythmic, and familial features of the disease were 
incorporated into the criteria, subdivided into major and minor categories according to the 
specificity of their association with ARVC. At that time, clinical experience with ARVC was 
dominated by symptomatic index cases and sudden cardiac death (SCD), which represented the 
severe end of the disease spectrum and only the ‘tip of the iceberg’. Consequently, the 1994 criteria 
were highly specific but lacked sensitivity for early and familial disease.  
 
In 2010, a new set of Task Force criteria were proposed,10,11 representing a working framework to 
improve the diagnosis and management of ARVC which relies on the demonstration of structural, 
functional, and electrophysiological abnormalities that are caused by or reflect the underlying 
histological changes. Technical advances in cardiovascular magnetic resonance (CMR) and 2-
dimensional echocardiography have improved the capability to image the right ventricle (RV) with 
reproducible measurements of volume and systolic function, which permits classification of 
severity and differentiation from normality. Previous diagnostic reliance on subjective assessment 
of RV wall thinning, wall motion abnormalities, and fatty infiltration of the myocardium by CMR 
has proven problematic, and has consequently been modified in the revise criteria. Recognition of 
significant fatty involvement without concomitant fibrosis of the RV in normal individuals renders 
this unique CMR capability of limited value. Late gadolinium enhancement (LGE) on CMR permits 
myocardial tissue characterisation in both the LV and RV. It can be difficult to be certain of late 
enhancement for characterisation of RV myocardium because of the thin wall of the RV and 
possible confusion with fat. 
1.2  Epidemiology of cardiomyopathy in Africa 
Heart failure has emerged as a dominant form of cardiovascular disease (CVD) in Africa, and holds 
great social and economic relevance because of its high prevalence, high mortality, and impact on 
young economically active individuals.12 The causes of heart failure in Africans remain, largely, 
non-ischaemic. Hypertension, cardiomyopathy, rheumatic heart disease, chronic lung disease and 
pericardial disease are the main contributors to the aetiology of cardiac failure in sub-Saharan 
Africa (SSA), accounting for over 90% of cases.12 In SSA, endemic cardiomyopathies include 
DCM, peripartum cardiomyopathy (PPCM), and endomyocardial fibrosis (EMF). Non-endemic 
cardiomyopathies apparently occur with the same frequency as in other parts of the world, and 
include HCM, ARVC and human immunodeficiency virus (HIV)-associated cardiomyopathy. 
Unlike in the developed world where the epidemiology of cardiomyopathy has been studied and 
described, there are no population-based incidence and prevalence studies of cardiomyopathy from 
Africa and other developing regions of the world. Hence, information on the epidemiology of 
cardiomyopathy in SSA is obtained, largely, from hospital-based studies.12 
 
Idiopathic dilated cardiomyopathy (DCM): In South Africa and Uganda, DCM accounts for 10-
17% of all cardiac conditions encountered at autopsy.13-15 In SSA, DCM occurs commonly in the 
third and fourth decades of life, with men affected twice as commonly as women. Two thirds of 
African patients with DCM, especially those who are more than 55 years of age, have persistently 
low arterial blood pressure, ventricular arrhythmias, and/or atrioventricular valve incompetence and 
die within 5 years of their first symptom.16,17 While there are no population based studies on the 
epidemiology of DCM in SSA, hospital series reveal that DCM accounts for 20% of admissions to 
African hospitals for heart failure.18 DCM has a 4 year mortality of 34% after onset of symptoms.19 
 
Peripartum cardiomyopathy (PPCM): PPCM is a cardiomyopathy occurring between the 
commencement of the last month of pregnancy and the end of the fifth month in the postpartum 
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period, in women without preexisting symptoms, signs, or history of heart disease, and in the 
absence of any identifiable cause for the cardiac failure.20-22 PPCM shares many common features 
with other forms of non-ischaemic cardiomyopathy.18 The important distinction is that women with 
PPCM are younger, have a higher rate of spontaneous recovery of LV function, and have a better 
survival than patients with idiopathic DCM.23,24 In a single centre prospective study of 100 South 
African patients with PPCM, 15% died, and only 23% recovered normal LV function after 12 
months of treatment, despite optimal medical therapy with ACE inhibitors and β blockers.25 In 
Nigeria, the contemporary mortality rate of PPCM is 42% over 25 years of follow-up.26 Co-morbid 
HIV infection has not been shown to affect the outcome in PPCM patients.27 PPCM has been 
shown to occur much more frequently in SSA than in developed countries. For instance, in the 
USA, the incidence of PPCM is 1 per 4000 births,28 while in South Africa it is estimated to be 1 per 
1000 births.29 The highest incidence occurs in the Zaria province of Nigeria, and is reported to 
occur in 1 per 100 deliveries.30 This observation of increased frequency in Nigeria may reflect 
volume overload as a result of ingestion of kanwa, a dried lake salt, while lying on heated mud beds 
twice daily for 40 days post-partum.30 It is important to note, however, that this high incidence rate 
of PPCM was observed before modern diagnostic modalities like echocardiography had come into 
mainstream use. 
 
Hypertrophic cardiomyopathy (HCM): HCM is an autosomal dominant disorder caused by mutation 
in genes encoding sarcomeric proteins, and has been shown to occur in 0.2% of 6680 unselected 
echocardiograms performed in Tanzania.31 HCM was previously thought to be rare amongst 
Africans.32 However, recent echocardiographic studies have dispelled that myth.33,34 For example, 
in Ghana, HCM is the third commonest form of cardiomyopathy, after DCM and EMF.35 In 
Ethiopia, HCM accounts for 34% of all cardiomyopathies diagnosed on echocardiography.36  
 1.3 The pathophysiology, natural history and outcomes in familial dilated 
cardiomyopathy 
The first report of familial DCM was by Evans.81 The first report of familial DCM in Africa 
described twin brothers in Uganda.37 Brink et al subsequently described the interesting condition of 
‘hereditary dysrrhythmic congestive cardiomyopathy’ in which prolonged QT interval is associated 
with ventricular arrhythmias and progressive dilatation of cardiac chambers.38 DCM in sibling 
brothers has also been reported in South Africa.39 Data from western populations demonstrate that 
15-25% of all patients with DCM have a first degree relative that also show evidence of DCM 
suggesting familial transmission.40  Furthermore, studies in South African patients with idiopathic 
DCM have revealed a common mitochondrial DNA variant that is associated with susceptibility to 
DCM in British and South African populations.41 Maharaj and colleagues did HLA typing in 62 
patients with DCM compared to 180 black normal controls to determine if immunogenetic factors 
could be involved in the pathogenesis of this condition.42 In keeping with studies from western 
countries,43,44 they demonstrated an association with HLA-DR1 and DRw10 antigens, implying that 
genetically determined immune response factors play a role in the pathogenesis of some individuals 
with DCM.45 While no mutations have been found in the cardiac actin, skeletal actin, and AMPK 
genes46 recently, mutations in the troponin T gene have been detected in a family with childhood 
onset DCM.47 
 
In 1990, Geisterfer-Lowrance et al reported the first evidence of a gene defect underlying a form of 
intrinsic heart-muscle disease: they found that a mutation in the gene encoding the contractile 
protein ß-myosin heavy chain results in familial HCM.48 Since then, mutations in several other 
genes, all encoding proteins of the myofibrillar apparatus, the fundamental contractile unit of the 
cardiomyocyte, have been found to cause familial HCM.49,50  These proteins include sarcomeric 
proteins (ventricular myosin light chains 1 and 2, cardiac troponin I and T, -tropomyosin, -
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cardiac actin) and an intra-sarcomeric cytoskeletal protein (myosin-binding protein C). Although the 
mechanisms by which mutations of the genes for these proteins lead to cardiac hypertrophy remain 
unclear, the elucidation of these gene defects provides important evidence of the primacy of 
impaired force generation in the pathogenesis of cardiac hypertrophy. Familial HCM is responsible 
for a small proportion of cases of cardiac hypertrophy. Nonetheless, it is of major clinical 
importance, since no specific therapy is available and it is the most common cause of sudden 
cardiac death (SCD) in young adolescents.51 Thus, the discovery of gene defects that cause familial 
hypertrophic cardiomyopathy also heralds the exciting prospect of improved and early diagnosis 
and the potential for developing specific, mechanism-based therapies. 52 
 
In contrast to familial HCM, inherited forms of DCM account for only about 30 percent of cases of 
DCM and are a major cause of severe heart failure necessitating heart transplantation.53 Most 
patients with idiopathic DCM initially present between the ages of 20 and 50 years, but the disorder 
may also affect children and the elderly.51 The most common initial manifestation is heart failure (in 
75 to 85 percent of patients), which is frequently advanced at presentation.52 The chief morphologic 
feature is biventricular dilatation. Heart weight is increased, indicating hypertrophy, but maximal 
LV free-wall thickness and septal thickness are typically normal because of the abnormally dilated 
chambers. Functionally, the chief defect is impaired systolic performance, as opposed to the 
diastolic dysfunction characteristic of familial HCM.53  
 
Although mutations in the gene for the extra-sarcomeric cytoskeletal protein dystrophin were 
identified some time ago as the cause of both muscular dystrophy (Duchenne type and Becker type) 
and X-linked DCM, the genetic causes of the inherited forms of DCM have, until recently, defied 
analysis.54 In addition to defects in dystrophin (which may also cause myocarditis and DCM as a 
result of cleavage by coxsackievirus B3),55 other defects that might be responsible for DCM include 
those affecting the genes for -cardiac actin56 and those for two proteins — emerin and lamin — 
that, like the dystrophin-gene defect, can cause both muscular dystrophy and DCM.57,58  
 
The identification of mutations in the gene for -cardiac actin as a cause of DCM was surprising. 
Previously, -cardiac actin had been regarded solely as a component of the sarcomere, and 
mutations in the gene for this protein, although distinct from those causing DCM, not unexpectedly 
were found to cause familial HCM.50 More recent evidence suggests that -cardiac actin may not 
only function as an important component of the sarcomere and, thus, be critically involved in force 
generation, but may also function as an intra-sarcomeric cytoskeletal protein that contributes to 
force transmission.59 Hence, it appears that the same genes causing familial HCM may be 
responsible for familial DCM too. 
 
1.4 The phenomenon of familial aggregation in peripartum cardiomyopathy 
The familial aspects of dilated and hypertrophic forms of cardiomyopathy have been reviewed in 
the sections above. There are several studies that suggest significant familial clustering of PPCM. 
Pierce et al described in a series of 17 patients with PPCM, three of whom had a definite family 
history of PPCM (i.e. 18% prevalence of familial disease among the probands).60  Massad et al 
published a case report of a woman with biopsy proven PPCM, whose sister had had a heart 
transplant for the same condition.61 Pearl described a 24 year old white woman of Mexican origin 
dying of PPCM 17 days after delivery of her baby, who had a mother who also died at age 34 years 
of PPCM, a week after delivering her fifth child, as well as a sister who also died of congestive 
cardiac failure two days in the puerperium.62 Voss et al  described the case of PPCM, where the 
patient died of cardiac failure in the puerperium, as had her mother and two of her sisters.63 Fett et 
al also reported a case of a mother and a daughter who both met the diagnostic criteria of PPCM.64 
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In a German study of PPCM patients, 15% were found to have probable familial cardiomyopathy, 
based on a positive family history of PPCM, DCM, SCD and arrhythmia.65 Further, two separate 
studies have reported on common variants associated with PPCM.66,67 A recent publication has 
reported on shared genetic predisposition between PPCM and DCM.68  
 
1.5 Risk factors and outcomes in peripartum cardiomyopathy 
Many authors have investigated risk factors for the development of PPCM. We have reviewed these 
previously.23 These postulated risk factors include African ancestry, advanced maternal age, 
multiparity, poor socioeconomic status, multiple pregnancy, hypertension and prolonged tocolytic 
use. We have previously argued strongly for a stricter definition of PPCM that excludes pregnancy-
related hypertensive disorders (including gestational proteinuric hypertension, eclampsia, pre-
eclampsia, and post-partum hypertension).23,69 In these hypertensive disorders of pregnancy, good 
LV recovery at six months is likely to be the norm, with minimal long term sequelae. This is 
contrasted with PPCM, where complete recovery of LV size and function occurs in about 30 to 50% 
of patients, with persistent LV dysfunction in the majority of survivors. Hence, it is our contention 
that hypertensive heart disorders of pregnancy should be viewed as a distinct clinical entity from 
PPCM, and not included in the clinical spectrum of PPCM, as is the current practice.23,69 In PPCM 
specifically, non-systematic studies have revealed siblings of PPCM patients demonstrating LV 
dilatation and LV dysfunction. Even more striking, however, is that PPCM appears to share similar 
predisposing factors and clinical features with other forms of idiopathic (non-ischaemic) DCM; 
hence our proposition that they may be different manifestations of the same disease.23 Further 
weight to support this view has been the shared genetic predisposition between PPCM and DCM, 
which is clearly not evident in those with HHFP.68 
 
 
Several researchers have investigated outcomes in PPCM. Generally, the mortality in PPCM varies 
from 18-56% at 1 year.70,71 In a prospective single centre South African study of 100 PCM patients, 
15% died, while only 23% normalised their LV function at 1 year, despite optimal medical 
therapy.25 
 
1.6 The Groote Schuur Hospital experience on cardiomyopathies 
At Groote Schuur Hospital (GSH), we have abundant experience in managing patients with DCM, 
HCM, PPCM, ARVC, LVNC and RCM, with many end-stage patients receiving orthotopic heart 
transplantation (OHT). Much of this experience goes back to the time of the performance of the 
world’s first heart transplant at GSH in 1967. We felt that it was timely to review our cumulative 
experience with these conditions, and to document the clinical phenotypes, clinical genetics and 
outcomes of our patients with these conditions, especially with the use of contemporary 
cardiovascular therapeutic agents. 
 
1.7 Rationalé for the study 
It is not clear whether the various phenotypic expressions of cardiomyopathy represent disparate 
clinical entities, or whether they are merely different forms of the same disease manifested 
differently in different circumstances. Furthermore, the familial aggregation of cardiomyopathy has 
not been studied systematically in an African setting. Moreover, the outcome of various 
cardiomyopathies in a contemporary African setting with current therapeutic modalities is 
unknown. Hence, we are unable to identify determinants of outcome as well as to prognosticate in 
the various cardiomyopathies. The proposed study envisages addressing these gaps in our 
knowledge, which will have implications for the management of patients with cardiomyopathy. 
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1.8 Hypothesis 
We hypothesise that cardiomyopathies are a caused by familial/genetic and non-familial/non-
genetic factors, and that disease onset, clinical and pathological features, disease progression and 
severity, and disease prognosis vary based on familial/genetic and non-familial/non-genetic 
aetiology. 
 
1.9 Study aims 
A number of studies have been conducted to test the above hypothesis. These studies aimed to 
investigate: 
1. The frequency and clinical genetics of familial dilated cardiomyopathy (FDC); 
2. The clinical characteristics and outcome of familial dilated cardiomyopathy compared to 
idiopathic dilated cardiomyopathy; 
3. Risk factors and outcomes of PPCM; 
4. The comparison of the clinical characteristics and outcome of PPCM versus hypertensive 
heart failure of pregnancy; 
5. The genetics and outcomes of HCM; 
6. Genotype-phenotype correlations of HCM in founder families examined by cardiac 
magnetic resonance imaging. 
 
 
We investigated the above aims in a cohort of patients followed up over a 16 year period (1996-
2009) at GSH. In particular, we were interested in exploring the demographic parameters of this 
group, survival and other outcome parameters, as well as the determinants of survival in specific 
cohorts. We also studied family pedigrees in order to be able to characterise the clinical genetics of 
familial DCM in this cohort. 
 
 
 
Chapter 2 
 
 
Methods 
 
 
A detailed description of the Methods is included in each of the chapters that follow. Briefly, the 
Methods are described below.    
 
2.1 Study design 
The sub-studies included in this thesis were designed either as retrospective analysis of information 
obtained from hospital records of patients previously seen at the GSH Cardiac Clinic or cross-
sectional studies of CMR imaging in probands and first degree relatives of patients with HCM from 
Tygerberg Hospital scanned at GSH. 
 
2.2 Subject selection 
The inclusion criteria for the study was that patients must have been diagnosed with 
cardiomyopathy, based on existing clinical case definitions. Patients were be identified from the 
GSH Cardiac Clinic and cardiac genetic database records.  
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2.3 Measurements 
A data collection database that incorporated patient demographic details, medical history and co-
morbidity, as well as details of imaging, laboratory and invasive investigations and management 
was utilised. 
 
2.4 Statistical Analysis 
Simple descriptive statistics were used both for data interpretation and to draw inferences about the 
population of patients that were studied. SPSS and STATISTICA were used for univariable and 
multivariable regression analysis and for performing correlations on risk factors and outcomes. 
Kaplan-Meier plots were used to demonstrate survival. 
 
2.5 Ethical considerations 
The study was carried out in the spirit of the Helsinki declaration. The aims, design and proposed 
conduct of the study reflect paragraph six of the Helsinki declaration, which reads: “The primary 
purpose of research involving human subjects is to improve prophylactic, diagnostic and therapeutic 
procedures and the understanding of the aetiology and pathogenesis of disease.” This study was 
formulated in compliance with principles delineated in the Helsinki declaration (last modified in 
2013). 
 
All research procedures were reviewed and approved by the institutional review board of the 
University of Cape Town Faculty of Health Human Research Ethics Committee. Initially, we 
obtained approval from the University of Cape Town Research Ethics Committee to perform a 
clinical and genetic study of all cardiomyopathies (UCT REC 197/1996). Subsequently, we were 
granted permission to perform a familial aggregation study of PPCM (UCT REC 020/2007). 
Furthermore, we also had approval for the study of HCM and other cardiomyopathies using CMR – 
the Cape Cardiac MRI initiative (UCT REC 307/2004). All subjects gave informed consent for their 
participation in these studies.  
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Chapter 3 
 
 
Frequency and clinical genetics of familial dilated 
cardiomyopathy in Cape Town: implications for the evaluation 
of patients with unexplained cardiomyopathy 
 
 
3.1 Introduction      
DCM is defined by the presence of LV systolic dysfunction and dilatation in the absence of 
abnormal loading conditions (hypertension, valve disease) or coronary artery, pericardial or 
congenital heart disease sufficient to cause global systolic impairment.5 Right ventricular dilation 
and dysfunction may be present but are not necessary for the diagnosis.72 DCM is an important 
cause of heart failure, as well as a common indication for heart transplantation.52 The clinical and 
morphological diversity of DCM reflect the broad spectrum of distinct underlying molecular and 
environmental causes.53 The prevalence of DCM is estimated to be 36.5 per 100, 000 in a United 
States population.73 There are, however, no population-based studies of the epidemiology of DCM 
in sub-Saharan Africa.12 Most cases of DCM are thought to be sporadic or acquired.74 However, in 
many cases the disease is inherited and is termed familial DCM, which may account for up 25-50% 
of DCM in Western populations.75-77  
 
Familial DCM is principally caused by genetic mutations in genes that encode cytoskeletal, nuclear 
and sarcomeric proteins in the cardiac myocyte.78 In addition, modifying genes, lifestyle and 
additional factors are reported to influence onset of disease, disease progression, and prognosis.79 
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Pedigree analysis in familial DCM is most consistent with autosomal dominant inheritance with 
variable penetrance.80 
 
To the best of our knowledge, there is no information on the frequency and clinical genetics of 
familial DCM in Africa. The aims of this sub-study were three fold: first, to describe the frequency 
of familial DCM in a series of patients who were diagnosed with DCM and followed-up in a 
cardiomyopathy clinic at the Cardiac Clinic at GSH in Cape Town from 01 February 1996 to 31 
December 2009; second, to document, through pedigree analysis, the likely modes of inheritance of 
familial DCM in the Cape Town cohort; and finally, to address the implications of the findings for 
the clinical evaluation of patients with unexplained DCM. 
 
3.2 Methods 
3.2.1 Study design 
The study was designed as a prospective hospital-based study of the frequency and clinical genetics 
of familial DCM in a cohort of DCM patients referred to the cardiomyopathy clinic in the Cardiac 
Clinic, GSH, Cape Town, South Africa. The frequency of familial DCM was based on a detailed 
family history in all individuals and family screening of first-degree relatives of probands with a 
positive history for confirmation of familial disease. Familial DCM was defined as the presence of 
DCM in at least one first degree relative of the proband and/or the presence of sudden unexplained 
death under the age of 35 years in a first degree relative. 
 
3.2.2 Study population 
We reviewed the medical records of all patients evaluated for a cause of cardiomyopathy from 01 
February 1996 and 31 December 2009. The patients in this study were seen in a dedicated 
cardiomyopathy clinic. All patients included in the study were those with DCM, as evidenced by 
clinical signs and symptoms of heart failure associated with a LV dilatation and a LV ejection 
fraction less than 50% on echocardiography or cardiac catheterisation. Patients with any of the 
following conditions were excluded: rheumatic or other intrinsic valvular heart disease, coronary 
artery disease (CAD), pericardial disease, chronic hypertension, congenital heart disease, 
myocarditis and any other systemic disease with cardiovascular sequelae such as diabetes, drug-
induced cardiomyopathy, haemochromatosis, neuromuscular disease, infantile endocardial 
fibroelastosis, EMF, amyloidosis, or myocarditis documented on endomyocardial biopsy (EMB) or 
associated with proven viral infection.  Patients with alcohol ingestion were included, since such 
persons may have a genetic predisposition to DCM. Furthermore, their exclusion could spuriously 
inflate the proportion of patients with familial DCM since a diagnosis of alcohol-induced 
cardiomyopathy might be made more readily in absence of a family history of DCM. For similar 
reasons, patients with PPCM were included. However, patients with HCM, RCM and tachycardia-
related cardiomyopathies were excluded.  
 
3.2.3 Clinical genetics 
A two to five generation family pedigree was constructed for every patient with DCM. If a subject 
with DCM had any first-degree relative that was also affected with DCM, those first-degree 
relatives were invited for screening for DCM by history, physical examination, electrocardiogram, 
echocardiography and cardiac catheterisation where indicated. For deceased relatives, medical 
records were reviewed when available. Relatives with other cardiac disorders that could account for 
LV dysfunction were excluded from the analysis. Pedigree analysis was performed for all affected 
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families for likely pattern of inheritance of familial DCM. Pedigrees were constructed using the 
Cyrillic 2.1 software programme (http://www.cyrillicsoftware.com/).  
 
3.2.4 Statistical analysis 
Results of quantitative variables are given as mean ± standard deviation (SD). Categorical variables 
are represented as number and percentage. Pearson’s chi-square or Fisher’s exact test were used to 
compare the relative frequency of characteristics between individuals. All P values are two-sided; 
and P values < 0.05 are considered to indicate statistical significance.  
 
3.2.5 Ethical considerations 
The study was approved by the University of Cape Town Faculty of Health Sciences Human 
Research Ethics Committee (REC Ref No. 197/96). All participants gave written informed consent 
to participate in the study. All eligible patients were asked for permission to invite their first-degree 
relatives (parents, siblings and children) to participate in the study.  
 
3.3 Results 
3.3.1 Frequency of familial DCM 
109 unrelated cases with DCM were studied, 29 of whom had familial disease; hence, the frequency 
of familial DCM was 26.6%. The 29 cases were derived from all the populations of Cape Town, 
and reflected the referral base of Groote Schuur Hospital; 15 (48.3%) were coloured/mixed ancestry 
African, 10 (34.5%) were black African, 4 (13.8%) were white African, and 1 (3.4%) was of Indian 
descent. A total of 40 individuals with familial DCM, belonging to the 29 different families with 
familial DCM, were identified through family screening.  
3.3.2 Characteristics of patients with familial DCM 
The 29 unrelated cases with familial DCM had a mean (±SD) age at diagnosis of 28.01 ± 15.3 years 
with a preponderance of males (n 21, 72.5%); these characteristics were comparable to the total of 
40 individuals with familial DCM from the 29 families who were studied. The age of individuals 
with familial DCM was significantly lower than that of patients with non-familial DCM, who had a 
mean age of 39.1 ± 12.6 at the time of diagnosis (p=0.001) (Table 3.1).  
 
Table 3.1. Clinical characteristics of patients with familial and non-familial DCM 
 
Characteristic Index cases with familial DCM  
(n = 29) 
Non-familial DCM 
 (n = 80) 
P value 
Age in years at diagnosis (mean ±SD) 28.01 ± 15.33 39.10 ± 12.6 0.001 
Gender (%) 
          Males 
          Females 
 
21 (72.4) 
8 (27.6) 
 
48 (60) 
32 (40) 
 
 
0.260 
Ethnicity (%) 
          Black African 
          White African 
          Indian ancestry 
          Coloured/Mixed ancestry 
 
10 (34.5) 
4 (13.8) 
1 (3.4) 
14 (48.3) 
 
35 (43.8) 
13 (16.3) 
0 (0) 
32 (40) 
 
 
 
 
0.602 
Home language (%) 
          isiXhosa 
          English 
          Afrikaans 
          Other 
 
8 (27.6) 
6 (20.7) 
14 (48.3) 
1 (3.4) 
 
32 (40) 
11 (13.8) 
35 (43.8) 
2 (2.5) 
 
 
 
 
0.417 
NYHA functional class (%) 
         Class I and II 
         Class III and IV 
 
8 (27.6) 
21 (72.4) 
 
19 (23.8) 
61 (76.3) 
 
 
0.110 
HR at initial presentation (bpm) ± SD 96.02 ± 17.98 94.89 ± 19.53 0.496 
Systolic BP (mmHg) ± SD 102.37 ± 15.05 101.78 ± 18.11 0.397 
LBBB (%) 5 (17.2) 29 (36.3) 0.123 
LVEDD (cm) ± SD 6.28 ± 1.19 6.84 ± 1.37 0.026 
LVEF (%)± SD 28.10 ± 10.98 24.68 ± 11.50 0.048 
DCM = dilated cardiomyopathy; NYHA = New York Heart Association; HR = heart rate; BP = 
blood pressure; LBBB = left bundle branch block; LVEDD = left ventricular end diastolic 
dimension; LVEF = left ventricular ejection fraction. 
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There was no difference in degree of effort intolerance measured by the New York Heart 
Association (NYHA) Functional Class at presentation between the index cases with familial and 
non-familial DCM (Table 3.1). The patients with familial and non-familial DCM also had similar 
heart rate and mean systolic blood pressure at presentation (i.e., 95.6 ± 23.3 beats per minute versus 
94.9 ± 19.5 bpm [p=0.496] and 100.1 ± 14.9 mmHg versus 101.8 ± 18.1 mmHg [p=0.397; 
respectively). Whilst the frequency of electrocardiographic left bundle branch block was lower in 
the familial cases (17.2%) compared to the non-familial cases (36.3%), the difference was not 
statistically significant (p=0.123). However, familial DCM cases had significantly less ventricular 
dilation than non-familial cases; the left ventricular end diastolic dimension (LVEDD) was 6.2 ± 
1.1 cm in familial DCM patients versus 6.8 ±1.4 cm in non-familial DCM patients, p=0.001 (Table 
3.1).  
 
3.3.3 Clinical genetics of familial DCM 
Table 3.2 contains a summary of the pedigree analysis of the families with DCM that were studied. 
Pedigree analysis of the 29 families was consistent with autosomal dominant (AD) inheritance in 21 
(72.4%) families. An autosomal recessive (AR) inheritance pattern was observed in 5 (17.2%) 
families. X-linked recessive (X-LR) inheritance was seen in 3 (10.4%) of the familial DCM 
families. The examples of family pedigrees with AD, AR, and X-LR inheritance are depicted in 
Figure 3.1, and the full list of pedigrees is available as supplementary information online at 
http://www.medicine.uct.ac.za/.  
 
Table 3.2. Clinical genetics of the 29 families with familial dilated cardiomyopathy 
Mode of inheritance  
          Autosomal dominant 
          Autosomal recessive 
          X-linked recessive 
Number (%) 
21 (72.4) 
5 (17.2) 
3 (10.4) 
Number of affected 1st-degree relatives per family (mean ±SD) 2.16 ± 1.14 
Number of 1st-degree relatives at risk per family (mean ±SD) 3.45 ± 2.23 
Number of families with a family history of SCD (%) 1 (3.4) 
Number families with affected 2nd degree relatives (%) 9 (31) 
SCD, sudden cardiac death under the age of 35 years 
 
 
The number of affected first-degree relatives per family was 2.16 ± 1.14.  In these 29 families with 
DCM, the number of first-degree relatives at risk was 3.45 ± 2.23 per family. One family (3.4%) 
had a clear history of a member with sudden cardiac death (SCD) before the age of 35 years. Of the 
29 families included in the analysis, 9 (31.0%) had second degree relatives who were affected. 
 
It is noteworthy that two of the 29 unrelated patients (7%) with familial DCM had at least one 
relative who was diagnosed with PPCM, confirming that some cases of PPCM are part of the 
spectrum of familial DCM. 
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Figure 3.1. Pedigrees and mode of inheritance 
Pedigree analysis of the 29 families was consistent with autosomal dominant inheritance (e.g. panel 
A) in 72.4% (N=21); autosomal recessive inheritance (e.g. panel B) in 17.2% (N=5) and X-linked 
recessive inheritance (e.g. panel C) in 10.4% (N=3). Filled symbol = phenotypically affected 
subject; empty symbol = unaffected subject; circle = woman; square = man; diamond = gender 
unknown; arrow = proband; bar crossing the symbol = deceased. All the pedigrees are available as 
supplementary material online at http://www.medicine.uct.ac.za 
 
3.4 Discussion 
In 1949, Evans was the first to report on familial cases of cardiomyopathy,81 and subsequently there 
have been many publications on familial DCM. This study extends the observations that have been 
made in Western populations to Africa. We show that familial DCM occurs in 26.6% of cases of 
DCM, that it is a disease of young males with an autosomal dominant pattern of inheritance in the 
majority of families. We also confirm that some cases of PPCM, which occurred in the context of 
familial DCM in two families, are part of the spectrum of familial DCM. 
 
The finding of familial disease in a quarter of DCM patients in this study is in line with several 
other reports that have found inherited disease to constitute 20 to 50% of DCM patients.73-75,82,83 A 
prospective echocardiographic study that screened first-degree relatives of patients with DCM 
estimated the rate of familial DCM at 20.3%,75 as 315 relatives of 59 index patients with DCM 
underwent screening with echocardiography, including coronary angiography for those older than 
40 years in order to exclude CAD. DCM was found in 18 relatives (20% of index patients), whereas 
only 5% had been suspected of having familial disease based on family history alone. In another 
prospective study of 56 probands with DCM, the definite familial DCM rate was estimated at 25%, 
where the diagnosis of familial diseased was based on first-degree relatives with a diagnosis of 
DCM on cardiac catheterisation or on autopsy, or a first-degree relative with both an 
echocardiographic LV end-diastolic dimension (LVEDD) greater than two standard deviations 
above the mean and a LV ejection fraction (LVEF) below 50%.19 When LV enlargement was taken 
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as a clinical indicator of DCM, two other studies found the frequency of familial DCM to range 
from 29% to 48%.84,85 
 
In our study, over 70% of patients with familial DCM were male. This male preponderance in DCM 
has been previously described.86,87 In SSA, DCM has been shown in hospital-based studies to occur 
twice as commonly in men as in women.88 Moreover, a study of 637 DCM patients, including 130 
patients with familial DCM, found that male patients constitute approximately 70% of both non-
familial DCM and familial DCM cohorts studied.89  
 
The finding of a younger age of onset of familial DCM compared to non-familial disease is also 
consistent with other studies and compatible with a genetic cause. Moretti and colleagues have 
found familial DCM patients to be younger than non-familial cases (40 years vs. 48 years).89 One of 
the earlier systematic studies of familial DCM by Michels et al also found the disease to occur at a 
younger age (mean age of onset of 32 years) when compared to patients with idiopathic DCM.90 A 
different study comparing familial DCM and non-familial DCM found that only a younger age of 
onset was predictive of familial disease; no other clinical or morphological features were useful in 
distinguishing the two entities from each other.85 Likewise, Grünig and co-investigators found that 
156 of 445 DCM patients confirmed to have familial DCM, were much younger than those without 
familial disease.91 Early-onset CVD is likely to be influenced by genetic factors more than late-
onset disease.92  
 
We found that at least 70% of familial DCM families demonstrated an autosomal dominant (AD) 
pattern of inheritance. This observation is supported by many prior publications. Familial DCM  has 
been reported most commonly with AD inheritance in up to 90% of cases.77,85,92,93 The genetic and 
clinical heterogeneity observed is in keeping with causation by multiple genes, with gene-
environment interactions altering expression of disease.85 To date, over 25 mutations have been 
described in autosomal genes that are causative of familial DCM.77,92 Some of the commonly 
mutated genes causing AD type of familial DCM include lamin A/C, beta-myosin heavy chain, 
alpha-myosin heavy chain, actin, alpha-actinin-2, metavinculin, desmin, sarcoglycan, troponin T, 
alpha-tropomyosin, titin and phospholamban.77,93 There are also genetic polymorphisms that are 
associated with an increased risk of developing DCM in some populations.41,94 
 
An AR pattern of inheritance may account for up to 10% of familial DCM, and is commoner in 
certain ethnic groups and in cases of infantile DCM.95 Unlike many other studies, we found a 
slightly higher rate of AR inheritance in our study: 17.2%. A mutation in cardiac troponin I has 
been shown to cause AR DCM in one family.96  
 
X-linked familial DCM has been reported in 5-10% of cases.87  X-linked types of familial DCM 
usually result from mutations in the dystrophin gene, which are commonly associated with skeletal 
muscle weakness and elevated levels of creatinine kinase.77,97,98 In some cases, DCM has been 
noted to be the only presenting feature of patients with Becker muscular dystrophy or in female 
carriers.99 Furthermore, Becker muscular dystrophy and DCM have been seen in the same family, 
suggesting that it may be difficult to draw conclusions about phenotype from genotype.100 Sporadic 
dystrophin mutations are also identified in sporadic forms of X-linked DCM.101 
 
The determination of inheritance patterns by clinical genetic analysis of familial DCM is not 
straight-forward. Use of family history and construction of a three- or four-generation family 
pedigree may not be sensitive enough, when used alone for screening. Often, the phenotypes of 
affected individuals are not sufficiently specific for familial DCM. Furthermore, familial DCM 
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demonstrates incomplete penetrance, age-dependent disease expression and variable expression.85 
Among individuals carrying the same gene mutation, there may be wide variability in phenotypic 
effects and disease severity both within and between families. Within the same family, the 
phenotype may range from subtle or no symptoms to development of arrhythmia, heart failure, 
sudden cardiac death, complication with stroke or need for cardiac transplantation.102 
 
The observations in this study have major implications for clinical practice. Inherited forms of 
cardiomyopathy are frequently responsible for heart failure that is otherwise unexplained, and often 
labeled as idiopathic cardiomyopathy before full evaluation has been conducted. Evaluation of 
familial cardiomyopathy should include not only the individual patient, but also the pattern of 
inheritance within the family and assessment for the presence of syndromic features. The last 10 
years have seen remarkable advances in genetics. Improvements in technology have lowered costs, 
such that clinical use of molecular genetic testing is rapidly expanding in South Africa103 and other 
parts of the world. Genetic counseling about the potential risks and benefits of genetic testing is an 
essential part of the clinical care of individuals and families with inherited heart disease. However, 
the likelihood of finding a responsible gene mutation varies among the different types of inherited 
cardiomyopathy. Both hypertrophic and right ventricular forms of cardiomyopathy have a relatively 
high likelihood of finding a responsible gene mutation when molecular genetic testing is properly 
applied. By contrast, the identification of pathogenic mutations in familial DCM is more 
challenging because of extreme genetic heterogeneity. Nevertheless, the clinical screening of family 
members who are at risk for an inherited form of cardiomyopathy leads to earlier identification, 
earlier treatment, and improved outcomes with or without molecular genetic testing. 
 
This sub-study has several limitations. First, a relatively small number of families are included. 
Second, all these patients were seen in a tertiary referral centre, where there may be referral bias, 
which may overestimate the true frequency of familial DCM. However, on the other hand, the 
number of familial DCM cases in our cohort may have been underestimated for at least two 
reasons: (1) A varying spectrum of cardiac abnormalities may be present in asymptomatic relatives 
of patients with familial DCM, hence, familial and sporadic types of the disease are not easily 
distinguishable by family history and clinical screening of first-degree relatives in the absence of a 
‘gold standard’ for diagnosis; (2) in our study, the diagnosis of familial DCM was based on family 
history, and screening of first degree relatives of individuals with a positive family history to 
confirm the presence of familial DCM. It is likely therefore that we report the minimum frequency 
of familial DCM, and that the screening of the individuals without a family history is likely to yield 
a higher prevalence of familial disease. 
 
3.5 Conclusions 
We have shown that familial DCM is common in African patients with unexplained DCM, 
occurring in a quarter of DCM patients studied. We also found that familial DCM has a predilection 
for males as well as an early age of onset, with the mean age at diagnosis being 28 years. Over 70% 
of the affected families demonstrated an autosomal dominant pattern of inheritance. These findings 
have major implications for the clinical evaluation of patients with unexplained cardiomyopathy 
(including those with PPCM), in whom family screening of first degree relatives for 
cardiomyopathy is indicated. 
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Chapter 4 
 
 
Clinical characteristics and outcomes of familial and idiopathic 
dilated cardiomyopathy in Cape Town: a comparative study of 
120 cases followed up over 14 years 
 
 
4.1 Introduction      
Cardiomyopathies are primary disorders of heart muscle associated with LV dysfunction and 
development of heart failure, in which the heart muscle is structurally and functionally abnormal in 
the absence of significant coronary artery disease, hypertension, valvular disease, pericardial 
disease or congenital heart disease sufficient to explain the observed myocardial abnormality.5 In 
SSA, DCM  accounts for 10% to 17% of all cardiac conditions encountered at autopsy, and for 17% 
to 48% of patients hospitalised for heart failure.12,33  
 
The Heart of Soweto study (a contemporary study examining the characteristics and burden of CVD 
in urban Africa) indicates that heart failure is the commonest cardiovascular diagnosis, with 
moderate-to-severe LV dysfunction present in 53% of cases, and 68% of those with heart failure 
diagnosed with DCM or hypertensive heart disease.104 While DCM occurs at any age, it is common 
in the third and fourth decades of life, with men affected twice as commonly as women. Two thirds 
of patients with DCM, especially those who are more than 55 years of age, have persistently low 
arterial pressure, ventricular arrhythmias, and/or atrioventricular valve incompetence and die within 
5 years of their first symptom.17 
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To the best of our knowledge, with the exception of PPCM,25 there are no studies of the outcome of 
DCM in a contemporary African setting. While many cases of DCM are thought to be sporadic or 
acquired, in up to 50% of patients, the disease is inherited and is termed familial DCM.105 Familial 
DCM is principally caused by mutations in genes encoding cytoskeletal, nuclear and sarcomeric 
proteins in the cardiac myocyte, often presenting with incomplete penetrance, variable expression 
and significant locus and allelic heterogeneity.106 Modifying genes, lifestyle and additional factors 
are reported to influence onset of disease, disease progression, and prognosis in familial DCM. It is 
of clinical interest to know whether the clinical characteristics and treatment modalities influence 
outcome in patients with familial DCM, and whether there are differences in clinical characteristics 
and outcome between those with familial disease compared to idiopathic cases of DCM. 
 
The purpose of this sub-study was to compare the clinical characteristics and outcome of patients 
with familial and idiopathic DCM in a contemporary African setting with access to a full range of 
proven medical and surgical interventions for heart failure, such as cardiac resynchronisation 
therapy (CRT) and OHT, which are available at GSH.107 
 
4.2 Methods 
4.2.1 Study design 
The sub-study was designed as a prospective hospital-based study of the clinical characteristics and 
outcomes of familial and DCM at GSH, Cape Town, South Africa. We reviewed the medical 
records of all patients diagnosed with idiopathic DCM, evaluated at GSH Cardiac Clinic from 
February 1, 1996 and December 31, 2009.  
 
4.2.2 Study population 
The patients in this study were seen in a dedicated cardiomyopathy clinic. All patients included in 
the study were diagnosed with using established criteria for DCM, based on evidenced by clinical 
heart failure associated with a LV dilatation and a LVEF less than 50% on echocardiography or 
cardiac catheterisation. Familial DCM was defined as the finding of a first-degree relative with 
DCM in a patient with unexplained DCM. The selection of the patients for inclusion in this study 
has been described in detail before. Patients with valvular heart disease, CAD, pericardial disease, 
chronic hypertension, congenital heart disease, myocarditis and any other systemic disease with 
cardiovascular sequelae were excluded.   
 
4.2.3 Data collection 
All patients had comprehensive clinical assessment. Information collected at the time of physical 
examination included history of medical co-morbidity, medications used, history of alcohol and 
tobacco use. Important clinical parameters including the pulse, blood pressure, oedema, the height 
of the jugular venous pressure, presence of murmurs and crepitations were recorded. Clinical 
assessment was complemented by chest radiography, electrocardiography, and detailed two-
dimensional and Doppler colour-flow echocardiography. Normal values for echocardiographic 
measurement were based on age and body-surface area. Cardiac catheterisation was performed, 
when appropriate, and tissue obtained at biopsy of right ventricular endomyocardium was examined 
by light microscopy, immunohistochemistry and electron microscopy by a pathologist with no 
knowledge of the family history of any patient.  
 
4.2.4 Statistical analysis 
Results of quantitative variables are given as mean ± SD. Categorical variables are represented as 
number and percentage. Pearson’s chi-square or Fisher’s exact test was used to compare the relative 
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frequency of characteristics between individuals. All P values were two-sided; and a P value <0.05 
was considered significant.  
 
Kaplan-Meier survival curves were constructed using the product-limit method, and were compared 
using the log-rank test. Kaplan-Meier curves were utilised to visualise the survival experience 
between familial and idiopathic DCM patients, and the focus is on mortality, rather than time to 
death, justifying the choice of Cox’s logistic regression rather than the Cox proportional hazards 
model. Age-, gender and race-adjusted survival curves for the general South African population 
were derived and compared with the Kaplan-Meier survival rates for the patients with idiopathic or 
familial DCM using the chi-square test.  Kaplan-Meier survival curves were constructed using 
STATA version 9.0 (STATA Corporation, College Station, TX, USA). Univariate and multivariate 
logistical regression analysis was used to determine predictors of death. 
 
4.2.5 Ethical considerations 
The study was approved by the University of Cape Town Faculty of Health Sciences Human 
Research Ethics Committee (REC Ref No. 197/96). All participants gave written informed consent 
to participate in the study. All eligible patients were asked for permission to invite their first-degree 
relatives (parents, siblings and children) to participate in the study.  
 
4.3 Results 
4.3.1 Clinical characteristics at presentation 
A total of 120 patients were studied, comprising 80 idiopathic DCM patients and 40 familial cases 
from 29 families. The familial DCM patients had a younger age at diagnosis compared to the 
idiopathic DCM patients, with mean ages of 25.6 ± 15.1 years and 39.1 ± 12.6 years (p=0.001), 
respectively, as reported elsewhere. 
 
The clinical symptoms and signs of patients with familial DCM were similar to those of patients 
with idiopathic DCM (Table 4.1). Electrocardiographic findings were similar between the two 
groups, with the exception of T wave inversion, which was found more commonly in familial 
patients compared to idiopathic DCM patients: 35 (87.5%) vs. 55 (68.8%), respectively (p=0.014), 
and pathological Q wave abnormalities which were found more commonly in idiopathic DCM 
(32.5%) than in familial cases (12.5%) (p=0.028). Patients with idiopathic DCM were more likely 
to have radiographic cardiomegaly, as found in 75/80 (93.8%) of idiopathic DCM patients 
compared to 28/40 (70%) of familial DCM patients (p=0.020). The radiographic findings were 
corroborated by echocardiography, where idiopathic DCM patients were found to have significantly 
larger LV end-diastolic dimensions (LVEDD) (p=0.001), lower LVEF (p=0.026) and fractional 
shortening (FS) (p=0.048) than the familial DCM cases.  
 
At cardiac catheterisation, the only difference noted was in the LVEF, which was found to be lower 
in idiopathic DCM patients compared to familial DCM patients (26.2 ± 9.7 vs. 31.07 ± 15.63 %, 
p=0.032). There were no differences in the histological characteristics on light microscopy between 
the two groups. There were no significant differences between familial and idiopathic DCM 
patients in relation to risk factors for CVD, lung disease, HIV infection and stroke. 
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Table 4.1. Clinical, radiographic, electrocardiographic and echocardiographic features at 
presentation 
 
Clinical characteristics Idiopathic DCM 
(N = 80) 
Familial DCM 
(N = 40) 
P-value 
NYHA FC (%) 
          Class 1 and 2 
          Class 3 and 4 
 
19 (23.8) 
61 (76.3) 
 
11 (27.5) 
29 (72.5) 
 
 
0.110 
Dyspnoea (%) 79 (98.8) 36 (90) 0.295 
Fatigue (%) 79 (98.8) 40 (100) 0.596 
Angina/chest pain (%) 9 (11.3) 4 (10) 0.489 
Palpitations (%) 19 (23.8) 10 (25) 0.513 
Heart rate (%) 94.89 ± 19.53 95.61 ± 28.32 0.496 
Blood pressure [systolic] (%) 101.78 ± 18.11 100.10 ± 14.94 0.397 
Blood pressure [diastolic] (%) 64.37 ± 12.82 70.29 ± 13.45 0.289 
Pedal oedema (%) 59 (73.8) 29 (72.5) 0.583 
JVP height [cm] (%) 
          Below 3cm 
          3cm to angle of jaw 
          Above angle of the jaw 
 
23 (28.7) 
28 (35.0) 
29 (36.3) 
 
11 (27.5) 
11 (27.5) 
18 (45) 
 
 
 
0.337 
Murmur (%) 
          No murmur 
          MR 
          MR + TR 
          ESM 
 
18 (22.5) 
35 (43.8) 
24 (30) 
3 (3.8) 
 
12 (30) 
13 (32.5) 
14 (35) 
1 (2.4) 
 
 
 
 
0.220 
S3 Gallop (%) 56 (70) 27 (67.5) 0.695 
Basal crepitations (%) 39 (48.8) 24 (60) 0.165 
Radiographic features 
 
   
Cardiothoracic ratio >50% (%) 75 (93.8) 28 (70) 0.020 
Radiographic pulmonary oedema (%) 43 (53.8) 24 (60) 0.412 
Electrocardiographic features 
 
   
Heart rate ± SD 92.85 ± 19.53 96.58 ± 23.02 0.498 
Sinus rhythm (%) 60 (75) 26 (65) 0.218 
QRS abnormalities present (%) 36 (45) 14 (35) 0.399 
Increased voltage (%) 40 (50) 22 (55) 0.583 
Presence of pathological Q waves (%) 26 (32.5) 5 (12.5) 0.028 
Left atrial hypertrophy (%) 19 (23.8) 8 (20) 0.318 
Left bundle brunch block morphology (%) 29 (36.3) 7 (17.5) 0.123 
Right bundle brunch block morphology (%) 2 (2.5) 0 (0) 0.518 
Left ventricular hypertrophy (%) 28 (35) 12 (30) 0.243 
Right ventricular hypertrophy (%) 1 (1.3) 0 (0) 0.721 
PR prolongation present (%) 2 (2.5) 0 (0) 0.311 
T wave inversion (%) 55 (68.8) 35 (87.5) 0.014 
Arrhythmia present (%) 
          No arrhythmia 
          Atrial fibrillation 
         Atrial flutter 
         Ventricular tachycardia 
         Paced rhythm 
 
60 (75) 
16 (20) 
0 (0) 
1 (1.3) 
3 (3.8) 
 
26 (65) 
10 (25) 
1 (2.5) 
2 (5) 
1 (2.5) 
 
 
 
 
 
0.179 
QRS duration (ms) 112.07 ± 11.93 109.98 ± 12.31 0.107 
Echocardiographic features 
 
   
Interventricular septal thickness (systole) ± SD 1.04 ± 0.36 1.15 ± 0.39 0.469 
Interventricular septal thickness (diastole) ± SD 0.92 ± 0.30 1.08 ± 0.36 0.389 
Left ventricular posterior free wall thickness 
(systole) ± SD 
1.10 ± 0.41 1.18 ± 0.42 0.292 
Left ventricular posterior free wall thickness 
(diastole) ± SD 
0.92 ± 0.32 0.96 ± 0.30 0.593 
Left ventricular dimension (systole) ± SD 5.54 ± 1.31 5.42 ± 2.13 0.602 
Left ventricular dimension (diastole) ± SD 6.84 ± 1.37 6.21 ± 1.13 0.001 
Left ventricular ejection fraction ± SD 24.68 ± 11.50 28.01 ± 10.51 0.026 
Left ventricular fractional shortening ± SD 12.10 ± 5.99 14.81 ± 7.86 0.048 
ESM, ejection systolic murmur; JVP, jugular venous pressure; MR, mitral regurgitation; NYHA 
FC, New York Heart Association functional class; TR, tricuspid regurgitation 
 
 
4.3.2 Medical therapy and outcome at last follow-up visit 
Familial and idiopathic DCM patients were on similar treatments. However, beta-blockers 
(p=0.007) and digoxin (0.028) were more commonly prescribed for idiopathic DCM patients (Table 
4.2). There were no differences in mortality, clinical features, cardiovascular complications or 
utilisation of OHT between idiopathic DCM and familial DCM patients at last follow-up (Table 
4.3). 
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Table 4.2. Medical therapy at follow-up 
 
Medical therapy at last follow-up visit Idiopathic DCM 
(N = 80) 
Familial DCM 
(N = 40) 
P-value 
Furosemide (%) 78 (97.5) 37 (92.5) 0.116 
ACE-I* or ARB** (%) 80 (100) 39 (97.5) 0.466 
Beta-blocker (%) 76 (95) 30 (75) 0.007 
Digoxin (%) 70 (87.5) 26 (65) 0.028 
Spironolactone (%) 62 (78.5) 25 (62.5) 0.072 
Calcium channel blocker (%) 0 (0) 3 (7.5) 0.169 
Warfarin (%) 22 (27.5) 12 (30) 0.445 
*ACE-I, angiotensin converting enzyme inhibitor; **ARB, angiotensin receptor blocker 
 
 
Table 4.3. Complications, treatment and outcome data 
 
Outcome data Idiopathic DCM 
(N = 80) 
Familial DCM 
(N = 40) 
P-value 
Median duration of follow-up in years (IQR) 5.58 (1.42 – 10.41) 4.58 (1.33 – 14.8) 0.063 
Death at the end of the median follow-up period 
(%) 
32 (40) 16 (40) 0.595 
Chronic heart failure (%) 63 (78.8) 32 (80) 0.515 
Intra-cardiac clot (%) 3 (3.8) 2 (5) 0.496 
Embolic phenomena (%) 2 (2.5) 1 (2.5) 0.505 
Pulmonary hypertension (%) 0 (0) 1 (2.5) 0.466 
Implantable cardioverter defibrillator insertion (%) 1 (1.3) 1 (2.5) 0.453 
Permanent pacemaker insertion (%) 2 (2.5) 1 (2.5) 0.513 
Cardiac resynchronisation therapy (%) 2 (2.5) 3 (7.5) 0.108 
Orthotopic heart transplantation (%) 15 (18.8) 11 (27.5) 0.116 
NYHA FC at last visit (%) 
          Class 1 and 2 
          Class 3 and 4 
 
50 (62.5) 
30 (37.5) 
 
17 (42.5) 
23 (57.5) 
 
 
0.205 
NYHA FC, New York Heart Association functional class 
 
On univariate logistic regression analysis, factors that increased the likelihood of mortality in both 
familial and idiopathic cases were an increased LVEDD (p=0.038) and LVESD (p=0.049), an 
elevated JVP (above the angle of the jaw) at the initial visit (p=0.028), pulmonary hypertension 
(p=0.025), the lack of OHT (p=0.004) and symptomatic heart failure with NYHA functional class 
III and IV symptoms at the last visit (p=0.017), as shown in Table 4.4a. On multivariate analysis, 
the significant predictors of mortality include lack of OHT (OR 4.7 [1.3 – 72.6], p=0.026) and 
NYHA class III and IV symptoms at the last visit (OR 3.8 [1.3 – 48.5], p<0.001).  
 
The use of digoxin in idiopathic DCM patients was associated with increased mortality (OR 1.6 [1.0 
– 3.9], p=0.037), but not in familial DCM patients (Table 4.4b).  
 
Table 4.4a. Logistical regression analysis for predictors of mortality in both familial DCM 
and idiopathic DCM 
 
Characteristic Univariate analysis Multivariate analysis 
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
LVESD 1.764 (1.133 – 2.747) 0.038 0.955 (0.770 – 1.184) 0.674 
LVEDD  1.719 (1.129 – 2.618) 0.049 1.117 (0.889 – 1.403) 0.341 
JVP (>AOJ vs. <AOJ) 5.600 (1.202 – 26.095) 0.028 1.808 (0.256 – 12.777) 0.553 
Pulmonary hypertension 
(yes vs. no) 
3.586 (1.086 – 13.660) 0.025 1.401 (0.941 – 2.360) 0.646 
Orthotopic heart 
transplantation (no vs. yes) 
8.053 (0.954 – 67.970) 0.004 4.717 (1.306 – 72.600) 0.026 
NYHA FC at last visit (class 
3 or 4 vs. class 1 or 2) 
12.473 (1.576 – 
98.703) 
0.017 3.848 (1.305 – 48.469) <0.001 
LVESD, left ventricular end systolic dimension; LVEDD, left ventricular end diastolic dimension; 
JVP, jugular venous pressure; NYHA FC, New York Heart Association Functional Class 
 
 
 
Table 4.4b. Logistical regression analysis for predictors of mortality in idiopathic DCM 
 
Characteristic Univariate analysis Multivariate analysis 
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Use of digoxin (yes vs. no) 4.267 (1.161 – 15.676) 0.008 1.617 (1.036 – 3.984) 0.037 
 
4.3.3 Survival analysis 
Figure 4.1A shows the Kaplan-Meier survival analysis, showing no survival difference between 
idiopathic DCM patients and familial DCM patients (p=0.739). The mortality rate at the end of a 
median follow-up period of 5 years was 40% in both groups (Table 4.3). In Figure 4.1B, when the 
survival of the idiopathic DCM patients is compared to controls matched for age, gender and race in 
the general South African population, mortality is higher in the idiopathic DCM group (p=0.001). 
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In Figure 4.1C, the survival of the familial DCM cohort is compared with the matched members of 
the South African population, and there is a strong trend towards increased mortality in the familial 
DCM group (p=0.053). In Figure 4.1D, the comparison of the transplant-free survival between 
idiopathic and familial DCM is depicted, showing no difference between the 2 groups (p=0.986). In 
Figure 4.1E, the comparison of the survival free of transplantation between idiopathic DCM 
patients and controls matched for age, gender and race in the South Africa (SA) population is 
demonstrated (p<0.001); and in Figure 4.1F the comparison of survival free of transplantation in 
familial DCM patients and controls matched for age, gender and race in the South Africa (SA) 
population is shown (p<0.001). Survival free of transplantation is worse for both groups when 
compared to the general population. 
 
A 
 
 
D  
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Figure 4.1. Kaplan-Meier survival plots 
 A, Comparison of survival in idiopathic DCM patients compared to familial DCM patients 
(p=0.739); B, Comparison of survival in idiopathic DCM patients compared to controls matched for 
age, gender and race in the South Africa (SA) population (p=0.001); and C, Comparison of survival 
in familial DCM patients compared to controls matched for age, gender and race in the South Africa 
(SA) population (p=0.053); D, Comparison of survival free of transplantation in idiopathic DCM 
patients compared to familial DCM patients (p=0.986); E, Comparison of survival free of 
transplantation  in idiopathic DCM patients compared to controls matched for age, gender and race 
in the South Africa (SA) population (p<0.001); and F, Comparison of survival free of 
transplantation in familial DCM patients compared to controls matched for age, gender and race in 
the South Africa (SA) population (p<0.001). 
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4.4 Discussion 
This study of 80 idiopathic DCM and 40 familial DCM patients has shown a number of important 
observations. Firstly, despite the more favourable age and LV function of the familial DCM, there 
was a high mortality of 40% after a median follow-up of five years that was similar to patients with 
idiopathic DCM. Second, the presence of symptoms of heart failure was the most important clinical 
predictor of mortality, which was significantly reduced by intervention with OHT. Thirdly, and of 
concern, the use of digoxin in patients with idiopathic DCM appeared to be associated with excess 
mortality.   
 
We show that patients with idiopathic DCM have greater LV dimension both in systole and diastole 
on echocardiography, more radiographic cardiomegaly, as well as lower contractile capacity on 
echocardiography and cardiac catheterisation. Furthermore, on ECG we found a greater prevalence 
of pathological Q waves in idiopathic DCM in the absence of coronary artery disease. Similarly, 
Grünig and colleagues have shown that ECG ST segment and T wave abnormalities occurred more 
frequently in familial DCM than in idiopathic DCM.91 However, other authors have failed to 
demonstrate ECG differences between familial and idiopathic cases of DCM.75,76,108 ECG features 
are not sufficiently specific or sensitive to distinguish between familial DCM and idiopathic DCM, 
and are not useful for clinical classification. In this study, as with most comparisons of familial 
DCM with idiopathic DCM,75,80,89 there were no reliable clinical or morphological parameters 
capable of distinguishing between familial and non-familial forms of DCM, apart from a younger 
age of onset.105 
 
We show that persistent symptoms of heart failure associated with NYHA functional class III or IV 
features are the most powerful predictor of mortality both in idiopathic and familial DCM. 
Similarly, Limongelli and colleagues have shown that, in cohort of 48 adolescents with idiopathic 
DCM, NYHA functional class III and IV, pro-brain natriuretic peptide and electrocardiographic LA 
enlargement were the most important predictors of adverse outcomes.109 Pasotti and co-
investigators also reported on a group of 27 consecutive patients with DCM and lamin A/C gene 
mutations and found that NYHA functional class III and IV and competitive sports were the 
significant predictors of all cardiovascular events, including death.110 Other important predictors of 
mortality in DCM patients, which were not confirmed in this study, include advanced age, 
protodiastolic gallop, failure of the myopathic ventricle to respond to inotropic stimulation, 
ventricular arrhythmias, prolonged ECG QRS duration, reduced LV function and late gadolinium 
enhancement (LGE) on cardiovascular magnetic resonance (CMR) imaging.111,112  
 
The annual mortality rate for a patient with heart failure is 10-13%, which is similar to the mortality 
rate of 50% after a median follow-up period that was found in this study.113 However, while the rate 
of progression is variable and influenced by several factors, symptomatic patients experience 
progressive deterioration, and 10-50% of symptomatic patients with heart failure may die within a 
year.114 Hence, it is important that clinicians should pay particular attention to medical management 
of persistent symptoms in DCM patients, with the aim of escalating management including use of 
CRT and transplantation, as NYHA class III and IV symptoms remain powerful predictors of 
mortality. The medical history therefore remains the most important tool for assessment of 
adequacy of treatment in DCM. 
 
The patients in this study were on good medical treatment, with more than 60% simultaneously 
receiving an ACE-inhibitor or ARB, a beta-blocker, spironolactone and digoxin. However, we 
found that beta-blockers and digoxin were more commonly prescribed in the idiopathic DCM 
group. The increased use of beta-blockers and digoxin in the idiopathic DCM may reflect that this 
group of patients had more severe disease, as evidenced by greater LVEDD and lower LVEF. It has 
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been observed by others that patients with familial DCM are less intensively treated with evidence-
based therapies for heart failure than patients with sporadic DCM.89  
 
Interestingly, digoxin appears to be a significant predictor of mortality in idiopathic DCM, but not 
in familial DCM patients. Evidence from old clinical trials which were conducted before the 
introduction of beta-blockers for the treatment of heart failure supports the use of digoxin in 
patients with LV systolic dysfunction for the treatment of heart failure, particularly in patients with 
advanced symptoms.115,116 There is, however, no evidence that digoxin improves survival – and, in 
fact, may worsen outcomes in DCM patients. The effect of digoxin therapy differs between men 
and women; digoxin therapy is associated with an increased risk of death from any cause among 
women with heart failure and depressed LV systolic function.117 The DIG trial, a study of almost 
6800 patients with symptomatic heart failure, LVEF below 45% and who were in sinus rhythm, 
assigned randomly to receive either digoxin or placebo, showed that after 3 years of follow-up: (1) 
there was no difference in survival between digoxin and placebo groups; (2) the patients on digoxin 
had reduced symptoms and hospitalisation for heart failure; (3) patients on digoxin had significant 
increase in non-heart failure deaths, including deaths from arrhythmia, particularly in women; and 
(4) that lower serum digoxin levels correlated with survival (the ideal serum level is 0.65-1.0 
nmol/l).118,119 The serum levels of digoxin were not monitored in our study. The results of our 
analysis suggest that clinicians should refrain from blanket prescription of digoxin for all DCM 
patients without monitoring of digoxin levels.  
 
The findings of this sub-study have several important implications for clinical practice and research. 
First, the presence of symptoms of heart failure with mild cardiac structural and functional 
abnormalities in relatives of patients with DCM is associated with a poor prognosis. Second, the 
study emphasizes the need to refer patients with DCM and persistent symptoms of effort intolerance 
for evaluation for life-saving interventions such as heart transplantation. There is anecdotal 
evidence that patients with DCM are not referred in a timely manner for OHT in South Africa. 
Finally, there is a need to review the use of digoxin in patients with heart failure in view of the 
mortality risk that has been shown in this study. It is prudent to monitor digoxin levels, together 
with serum potassium and renal function, in all patients in view of the correlation of serum levels 
with mortality.119  
 
While this sub-study has important findings for clinical practice, it also has several limitations. 
First, generalization of findings from this study may be limited by the relatively small sample size. 
Second, this study population is dominated by patients with familial DCM that is typical of a 
tertiary referral clinic.  
 
 4.5 Conclusions 
In conclusion, DCM due to familial and non-familial causes is associated with a high mortality 
despite optimal medical and surgical therapy. Patients with persistent symptoms of heart failure 
despite optimal medical therapy need to be considered and referred for early assessment for OHT 
and other life-saving interventions. 
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Chapter 5 
 
 
Persistent symptoms of heart failure predict mortality in 
Africans with peripartum cardiomyopathy 
 
 
 
5.1 Introduction      
There is a paucity of studies of mortality and predictors of outcome in patients with peripartum 
cardiomyopathy (PPCM) who live in Africa where the condition is endemic.25,33,120 Sliwa and 
colleagues have reported a prospective study of 80 patients with PPCM who had a 25% case fatality 
rate at 2 years of follow-up which was not affected by HIV infection.120 There are, however, widely 
varying estimates of the survival rate in patients with PPCM. Amos et al observed no mortality in 
55 patients followed up over an average of 43 months during a 13 year period,121 while Brar et al 
described a case fatality rate of 3.3% over a 4.7 year follow-up.122 Mortality rates of 9.3% were 
observed by Goland and colleagues in the United States over a mean follow-up period of 19 
months,123 and Duran and co-authors described a mortality of 30% in 33 in Turkish patients 
followed-up between 1995 and 2007.124 These varying estimates may be related to differences in 
case selection and possibly the inclusion of patients with hypertension-related heart failure.23 
 
The aims of this study were to establish the case fatality rate and predictors of death in a 
prospective cohort of consecutive patients with PPCM who were identified over 14 years at a 
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tertiary hospital. Patients enrolled into the study were evaluated for PPCM at the Cardiac Clinic, 
GSH.  
 
5.2 Methods 
5.2.1 Study design 
The sub-study was designed as a hospital-based study of the case fatality rate and predictors of 
death in a prospective cohort of consecutive patients with PPCM who were identified over 14 years 
at a tertiary hospital - GSH, Cape Town, South Africa. We reviewed the medical records of all 
patients diagnosed with idiopathic PPCM, evaluated at GSH Cardiac Clinic from February 1, 1996 
and December 31, 2009.  
 
5.2.2 Study population 
The patients in this study were seen in a dedicated cardiomyopathy clinic. All patients included in 
the study were diagnosed using established criteria for PPCM,22 based on evidenced by clinical 
heart failure associated with a LV dilatation and a LVEF less than 45% on echocardiography, either 
in the last trimester of pregnancy or in the first 5 months post-delivery.  The selection of the patients 
for inclusion in this study has been described in detail before.213  
 
5.2.3 Data collection 
All patients had comprehensive clinical assessment. Information collected at the time of physical 
examination included history of medical co-morbidity, medications used, history of alcohol and 
tobacco use. Important clinical parameters including the pulse, blood pressure, oedema, the height 
of the jugular venous pressure, presence of murmurs and crepitations were recorded. Clinical 
assessment was complemented by chest radiography, electrocardiography, and detailed two-
dimensional and Doppler colour-flow echocardiography. Normal values for echocardiographic 
measurement were based on age and body-surface area.  
 
5.2.4 Statistical analysis 
Simple descriptive statistics were used for data interpretation and to draw inferences about the 
population of patients studied. Results of quantitative traits are given as means ± SD. Categorical 
traits are represented as number and percentage. Pearson’s chi-square for categorical variables, 
Student’s t test for continuous variables or Fisher’s exact test for non-parametric distributions were 
used to compare the relative frequency of characteristics between individuals. All P values were 
two-sided; and P values above 0.05 were considered not to indicate statistical significance. 
Univariate and multivariate logistical regression analysis was used to determine predictors of death. 
 
5.2.5 Ethical considerations 
The study was approved by the University of Cape Town Faculty of Health Sciences Human 
Research Ethics Committee (REC Ref No. 197/96). All participants gave written informed consent 
to participate in the study. All eligible patients were asked for permission to invite their first-degree 
relatives (parents, siblings and children) to participate in the study.  
 
 5.3 Results 
5.3.1 Baseline characteristics and pregnancy features 
Table 5.1 shows the demographic and clinical characteristics of the 30 participants in this study. 
The mean age was 31.45 ± 7.48 years. Three (10%) patients were expecting twins in the index 
pregnancy. All the patients developed symptoms of congestive heart failure in the postpartum 
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period: 9 (30.0%) in the first week after delivery; 7 (23.3%) between the end of the first week and 
first month postpartum; and 14 (46.7%) after the first month but before the end of the fifth month in 
the puerperium. The left ventricular end systolic dimension (LVESD) and left ventricular end 
diastolic dimension (LVEDD) were 6.85 ± 0.74 cm and 7.39 ± 1.13 cm, respectively. The mean left 
ventricular ejection (LVEF) fraction on echocardiography was 23.84 ± 8.33 at baseline and 31.28 ± 
11.39 at the last-follow up visit. 
 
5.3.2 Follow-up and outcomes 
Study subjects were followed-up for a median of 4.33 years (range 0.16 – 13.8 years), during which 
5 (16.7%) patients died. 24 (80%) patients, including those who died, remained in chronic heart 
failure throughout the period of study (Table 2). Other complications included intra-cardiac 
thrombus formation (16.7%), pulmonary hypertension (13.3%), atrial fibrillation (10.0%), and 
stroke (6.7%). One patient had cardiac resynchronisation therapy and another patient had orthotopic 
heart transplantation. At the last visit, 18 (72.0%) patients had NYHA functional class I and II 
symptoms, and 7 (28.0%) had class III and IV symptoms. 8 (26.7%) women improved their LVEF 
by more than 10% during the study period, while the rest either remained the same or worsened. 
However, none of these PPCM patients recovered their LVEF to greater than 50%. On multivariate 
logistic regression analysis, NYHA functional class III/ IV status at last visit was the only 
significant independent predictor of mortality (OR 3.11 [C.I. 1.33 − 11.98], p=0.047).  
 
Table 5.1. Clinical characteristics of patients diagnosed with PPCM 
Clinical characteristics of PPCM patients (N=30)  
Age (years) ± SD 31.45 ± 7.48 
Age > 30 years (%) 17 (56.7) 
Unemployment 10 (33.3) 
Parity ± SD 2.40 ± 0.73 
Gravidity ± SD 2.42 ± 0.68 
Multipara (%) 21 (70.0) 
Twin pregnancy (%) 3 (10) 
Tocolytic therapy (%) 1 (3.3) 
Tobacco smoking 
         Never smoker 
         Former smoker 
         Current smoker  
 
21 (70.0) 
2 (6.7) 
7 (23.3) 
Diagnosis delay in weeks ± SD 1.43 ± 0.54 
CTR > 50% (%)  29 (97.6) 
Heart rate (bpm) ± SD 86.3 ± 17.82 
QRS duration (ms) ± SD 109.50 ± 12.17 
LVESD  (cm) ± SD 6.85 ± 0.74 
LVEDD (cm) ± SD 7.39 ± 1.13 
LVEF baseline (%) ± SD 23.84 ± 8.33 
LVEF at last follow-up (%) ± SD 31.28 ± 11.39 
Heart failure therapy at last follow-up visit (%) 
         Furosemide 
         ACE-I/ARB 
         B-blocker 
         Digoxin 
         Spironolactone 
         Warfarin 
 
30 (100.0) 
30 (100.0) 
28 (93.3) 
23 (76.7) 
27 (90.0) 
9 (30.0) 
ACE-I, angiotensin con verting enzyme;  ARB, angiotensin receptor blocker; LVEDD, left 
ventricular end-diastolic dimension;  LVESD, left ventricular end-systolic dimension;    LVEF, 
left ventricular ejection fraction; PPCM, peripartum cardiomyopathy 
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Table 5.2. Outcomes in PPCM patients during follow-up of 14 years (median follow-up of 4.3 
years) 
 
Outcomes in PPCM patients Proportion affected  
Death 5 (16.7) 
Chronic heart failure 24 (80.0) 
Atrial fibrillation 3 (10) 
Cardiac resynchronisation therapy 1 (3.3) 
Intra-cardiac thrombus 5 (16.7) 
Stroke 2 (6.7) 
Pulmonary hypertension 4 (13.3) 
Orthotopic heart transplant 1 (3.3) 
NYHA functional class at last visit 
          Class 1 and 2 
          Class 3 and 4 
 
18 (72) 
7 (28) 
NYHA, New York Heart Association 
 
 
 
 5.4 Discussion 
To the best of our knowledge, we present the longest follow-up study of PPCM in Africans which 
provides four insights. First, we show that the case fatality rate is about 16.7% over a median of 4.3 
years in patients on modern medical therapy, a finding that is consistent with the largest study of 
outcome in PPCM.123 The outcome in this study is better than the series of Sliwa et al in 
comparable African women from Johannesburg where a case fatality rate of 25% was reported at 2 
years of follow-up.120 The reasons for the differences in outcome between the Cape Town and 
Johannesburg cohorts are not clear. Second, we confirm the association of PPCM with adverse 
outcomes including chronic progressive congestive heart failure, arrhythmia, thromboembolic 
complications (affecting the cerebral, coronary, mesenteric, peripheral and pulmonary vascular 
beds), sudden cardiac death within 3 months from diagnosis, and premature cardiovascular 
mortality.23,124  Third, we show in this study that chronic heart failure was common, occurring in 
80% of patients studied, and with virtually no normalization in left ventricular dysfunction. By 
contrast, American women with PPCM show recovery in almost 50% of cases.125 Our findings 
support the recommendation for long-term treatment and monitoring of patients with PPCM.25,120 
Finally, we found the persistence of symptoms of heart failure to be the strongest predictor of death 
in patients with PPCM. The persistence of symptoms in patients with PPCM on full medical 
therapy should therefore prompt the consideration of additional interventions, such as early 
evaluation for orthotopic heart transplantation.  
 
The major limitation of this study is the relatively small sample size of participants. PPCM is a 
relatively uncommon condition, and the numbers studied are typical of other contemporary studies 
of this condition. 
 5.5 Conclusions 
PPCM still has a high mortality, particularly in those women with persistent symptoms of heart 
failure. PPCM is often associated with adverse outcomes including chronic progressive congestive 
heart failure, arrhythmia, thromboembolic complications (affecting the cerebral, coronary, 
mesenteric, peripheral and pulmonary vascular beds), sudden cardiac death within three months 
from diagnosis, and premature cardiovascular mortality. Failure of normalisation of LV function is 
common. The persistence of symptoms of heart failure is the strongest predictor of death in patients 
with PPCM. The persistence of symptoms in patients with PPCM on full medical therapy should 
therefore prompt the consideration of additional interventions, such as early evaluation for OHT.  
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Chapter 6 
 
 
Pregnancy-associated heart failure: A comparison of clinical 
presentation and outcome between hypertensive heart failure of 
pregnancy and idiopathic peripartum cardiomyopathy 
 
 
6.1     Introduction 
PPCM is defined as a myocardial disorder of unknown cause, characterised by marked impairment 
of LV systolic function, with development of heart failure towards the end of pregnancy and in the 
months following delivery, in women without pre-existing heart disease, and in the absence of any 
other identifiable cause of peripartum heart failure.21,22 Although the aetiology of PPCM is poorly 
understood,23,126 many authorities consider pregnancy-induced hypertension (PIH) to be a risk 
factor for PPCM.20,126-129 Furthermore, it has been postulated that hypertensive heart failure of 
pregnancy (HHFP), defined as the occurrence of peripartum heart failure in association with any 
form of hypertension, and PPCM may represent a spectrum of the same disease which has a 
common pathophysiological pathway.130 
 
Our group has proposed a clear case definition of PPCM, noting that PPCM should be a diagnosis 
of exclusion that precludes all other known causes of peripartum heart failure, including 
hypertension.23,69 Since the seminal description of PPCM by Demakis in 1971, where preeclampsia 
 
90 
 
was found in 22% of the 27 patients studied,20 it has been unclear what the role of PIH in PPCM is. 
Indeed, many authors have described great variability in the prevalence of PIH in PPCM, with 
preeclamptic patients accounting from 15 to 89% of PPCM patients reported in the different 
studies.20,70,121,123,127-129,131-133 It is has been suggested that the inclusion of patients with varying 
degrees of gestational hypertension, in the index as well as previous pregnancies, has contributed 
significantly to the discrepancy in reported characteristics of PPCM.22,23,134 
 
We have performed a study of the clinical characteristics and outcome of a consecutive series of 
patients with a new diagnosis of pregnancy-associated heart failure occurring in the last trimester of 
pregnancy or puerperium in Cape Town. We investigated whether there were significant differences 
in time of onset of symptoms, clinical profile, and outcome between HHFP cases compared to 
patients with unexplained PPCM, in order to assess whether they can be considered to be a 
spectrum of the same disease, or whether they should be classified differently. 
 
6.2 Methods 
6.2.1. Study design 
This was a prospective, longitudinal hospital-based case-comparison study of HHFP to PPCM, in 
patients presenting with heart failure between the last month of pregnancy and the fifth postpartum 
month, who had been referred to the Cardiac Clinic at GSH in Cape Town, South Africa. 
We invited clinicians to refer patients with a new diagnosis of heart failure occurring in the last 
trimester or puerperium for enrollment into a study of risk factors of PPCM. The exclusion criteria 
were a known cardiac lesion; in particular, valvular heart disease, previous anthracycline exposure, 
ischaemic heart disease, a congenital heart lesion, and metabolic and systemic disorders with 
cardiovascular sequelae including diabetes mellitus and thyroid disease. Patients with any form of 
hypertension in pregnancy (including PIH) were included in the study; the latter patients were 
classified as HHFP. The study participants were between February 1, 1996 and December 31, 2009 
in a specialist cardiomyopathy clinic. The median follow-up for PPCM was 3.5 years and 6 years 
for HHFP. 
 
6.2.2. Definition of HHFP and PPCM 
The diagnosis of HHFP was based on the presence of clinical heart failure associated with any form 
of hypertension (i.e., chronic hypertension, gestational proteinuric hypertension, preeclampsia, 
eclampsia and postpartum hypertension), occurring in women between the last month of pregnancy 
and the first 5 months of the postpartum, in the absence of pre-existing heart disease, and any other 
identifiable cause of peripartum heart failure besides hypertension. Even though most of this group 
of study subjects had evidence of depressed systolic function (LVEF less than 45%) shortly after 
delivery, on echocardiography, there was no restriction on subject selection based on 
echocardiographic parameters. 
 
The standard definition of PPCM was applied; the patients with PPCM needed to fulfill 
echocardiographic criteria of a left ventricular ejection fraction (LVEF) below 45%, left ventricular 
fractional shortening below 28%, and a left ventricular end diastolic dimension greater than 5.5cm 
or greater than 2.7cm/m2.21 Patients with any form of hypertension, preeclampsia or eclampsia were 
excluded from the PPCM group. 
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6.2.3. Data collection 
There were 36 patients with PPCM that were enrolled in the study and 6 of these were subsequently 
lost to follow-up, and were not included in the analysis. All patients with a diagnosis of HHFP were 
included in the analysis. All patients had comprehensive clinical assessment, complemented by 
chest radiography, electrocardiography (ECG), two-dimensional and Doppler colour-flow 
echocardiography, and cardiac catheterisation, when appropriate. Blood was taken for full blood 
count, serum creatinine, urea and electrolytes. The primary imaging modality used to confirm the 
diagnosis was transthoracic two-dimensional and Doppler echocardiography. As the analysis period 
for the study is over 14 years, the echocardiographic assessments were performed by different 
cardiologists and sonographers at different time points in the follow-up, and some of these 
echocardiographic studies were incomplete. In the end, we were able to establish the vital status of 
30 PPCM and 53 HHFP patients at the end of the follow-up period. 
 
6.2.4. Statistical analysis 
Results of quantitative measurements are given as means ± SD. Categorical traits are represented as 
number and percentage. Pearson’s chi-square or Fisher’s exact test were used to compare the 
relative frequency of characteristics between the two groups of patients. All P values are two-sided; 
and P values < 0.05 are considered to be statistically significant. Survival analysis was performed 
using Kaplan-Meier plots. 
 
 
 
6.2.5. Ethical considerations 
This sub-study was approved by the University of Cape Town Faculty of Health Sciences Human 
Research Ethics Committee. All patients gave informed consent for participation in the study, and 
the study complies with the Declaration of Helsinki. 
 
6.3 Results 
6.3.1. Baseline characteristics 
A total of 83 female patients were included in this study (shown in Table 6.1). PPCM patients had 
an average age of 31.5 ± 7.5 years and HHFP patients had a similar mean age of 29.6 ± 6.6 years (p 
= 0.22). Nine (30%) of PPCM patients developed heart failure in the first week after delivery, 7 
(23.3%) after the first week but before the end of the first postpartum month, and 14 (46.7%) after 
the first month, but before the end of fifth postpartum month. In contrast, the HHFP patients 
presented earlier, with 45 (84.9%) developing heart failure in the last month of pregnancy, 6 
(11.3%) in the first postpartum week, and 2 (3.8%) between the first and fifth postpartum months 
(p<0.001) (as depicted in Figure 6.1). Twin pregnancy occurred more commonly in PPCM patients 
(p = 0.04), as did smoking (p = 0.02). A family history of hypertension (p<0.001) and a history of 
hypertension in a previous pregnancy (p<0.001) were found more commonly in HHFP patients. 
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Figure 6.1. Clinical characteristics of patients with peripartum cardiomyopathy (PPCM) and 
hypertensive heart failure of pregnancy (HHFP) at the initial presentation with heart failure 
Clinical characteristics 
 
PPCM 
(N=30) 
HHFP 
(N=53*) 
P-value 
Ethnicity 
          Black/African 
          Coloured/Mixed ancestry 
 
18 (60.0) 
12 (40.0) 
 
30 (56.6) 
23 (43.4) 
 
0.820 
Age at diagnosis 31.5 ± 7.5 29.6 ± 6.6 0.223 
Onset of symptoms in relation to pregnancy 
          Last trimester 
          Within 1st week after delivery 
          > 1st week,<1st month after delivery 
          > 1st month,<5th month after delivery 
 
0 (0) 
9 (30.0) 
7 (23.3) 
14 (46.7) 
 
45 (84.9) 
6 (11.3) 
0 (0) 
2 (3.8) 
 
<0.001 
Twin pregnancy 3 (10.0) 0 (0) 0.04 
Family history of hypertension 3 (10.0) 35 (66.0) <0.001 
History of hypertension in previous 
pregnancy 
0 (0) 17 (32.1) <0.001 
NYHA FC at presentation 
          Class 1 and 2 
          Class 3 and 4 
 
10 (33.3) 
20 (66.7) 
 
9 (16.9) 
44 (83.1) 
 
0.163 
Pedal oedema 24 (80.0) 19 (35.8) <0.001 
Parity 2.4 ± 0.7 2.2 ± 0.6 0.591 
Gravidity 2.4 ± 0.7 2.2 ± 0.6 0.595 
Smoking 
          Never smoker 
          Former smoker 
          Current smoker 
 
21 (70.0) 
2 (6.7) 
7 (23.3) 
 
33 (62.3) 
15 (28.3) 
5 (9.4) 
 
0.024 
Alcohol 
          Never drinker 
          Former drinker/moderate use 
          Excessive intake 
 
23 (76.7) 
4 (13.3) 
3 (10.0) 
 
45 (89.4) 
7 (13.2) 
1 (1.9) 
 
0.244 
HIV seropositive 3 (10.0) 6 (11.3) 0.582 
Delay from symptom onset to clinical 
assessment (months) 
2.7 ± 1.4 1.1 ± 0.3 <0.001 
Systolic blood pressure 105.9 ± 16.2 162.3 ± 28.4 0.003 
Diastolic blood pressure 63.5 ± 9.6 105.0 ± 12.1 <0.001 
Basal rales 16 (53.3) 41 (77.4) 0.007 
Murmur 
          No murmur 
          MR 
          MR + TR 
          ESM 
 
10 (33.3) 
13 (43.3) 
7 (23.3) 
0 (0) 
 
35 (66.0) 
14 (24.6) 
3 (5.7) 
1 (1.9) 
 
0.006 
 
(*48 [90.6%] of the 53 HHFP patients had a diagnosis of preeclampsia; NYHA FC=New York 
Heart Association functional class; MR, mitral regurgitation; TR, tricuspid regurgitation; ESM, 
ejection systolic murmur) 
 
Figure 6.1. Onset of heart failure symptoms in hypertensive heart failure of pregnancy and 
peripartum cardiomyopathy 
 
 
6.3.2. Clinical characteristics at presentation 
Three (10%) of the PPCM patients and 6 (11.3%) of the HHFP patients were HIV-infected (p = 
0.582). A sensitivity analysis revealed that there were no differences between patients with and 
without HIV infection. The systolic and diastolic blood pressures measurements were 105.9 ± 16.2 
mmHg and 63.5 ± 9.6 mmHg in PPCM patients and 162.3 ± 28.4 mmHg and 105.0 ± 12.1 mmHg 
in HHFP patients (p = 0.003 and p<0.001, respectively). Basal rales were detected in 16 (53.3%) of 
PPCM patients and 41 (77.4%) of HHFP patients (p = 0.007). Peripheral oedema was present in 
80% of PPCM patients compared to 35.8% of HHFP patients (p<0.001). 
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6.3.3. Radiographic, electrocardiographic and echocardiographic features 
A cardiothoracic ratio (CTR) greater than 50% was found more commonly in PPCM compared to 
HHFP patients (p<0.001), as shown in Table 6.2. Radiographic evidence of pulmonary oedema was 
noted more frequently in HHFP patients, in keeping with the clinical detection of rales (p = 0.010). 
Higher heart rate was found in HHFP patients (p = 0.014). On electrocardiography (ECG), atrial 
fibrillation (p = 0.028), QRS abnormalities (p = 0.001), relatively longer QRS duration (p<0.001), 
left atrial hypertrophy (p = 0.030), and left bundle brunch block (p = 0.002), and T wave inversion 
(p<0.001) were detected more commonly in PPCM patients than in HHFP patients. As expected, 
left ventricular hypertrophy (LVH) (p = 0.021) was seen more frequently in HHFP patients. On 
echocardiography, patients with HHFP had greater ventricular septal thickness in diastole (p = 
0.013) as well as greater LV posterior free wall thickness in systole (p = 0.002). PPCM patients had 
larger LV dimensions both in systole and diastole (p<0.001 and p<0.001, respectively), as well as 
lower LVEF and LV fractional shortening (p<0.001 and p<0.001, respectively) compared to HHFP 
patients. 
6.3.4 Medical management at follow-up 
With regards to heart failure therapy, significantly more PPCM patients were receiving furosemide 
(p<0.001), angiotensin converting enzyme-inhibitor (ACE-I)/angiotensin receptor blocker (ARB) 
(p<0.001), β-blockers (p<0.001), spironolactone (p<0.001) and digoxin (p<0.001) compared to 
HHFP patients (Figure 6.2). However, more HHFP patients were on calcium channel blockers 
(CCB) for treatment of hypertension than PPCM (p = 0.014). Warfarin was prescribed more 
commonly for consequent atrial fibrillation, and LV thrombus for PPCM patients (p = 0.030). 
Table 6.2. Radiologic, electrocardiographic, and echocardiographic findings at initial 
presentation with heart failure 
 
Radiologic, electrocardiographic, 
echocardiographic and laboratory 
findings  
PPCM 
(N=30) 
HHFP 
(N=53) 
P-value 
Radiographic cardiothoracic ratio>50% 29 (96.7) 22 (41.5) <0.001 
Radiographic pulmonary oedema  16 (53.3) 45 (89.4) 0.010 
ECG heart rate 86.3±17.8 106.9±27.4 0.014 
ECG QRS abnormalities 8 (27.6) 1 (1.9) 0.001 
ECG voltage abnormality 8 (27.6) 31 (58.5) 0.816 
ECG left anterior hemiblock 9 (30.0) 5 (9.4) 0.03 
ECG Q wave 5 (16.7) 5 (9.4) 0.484 
ECG left bundle branch block 6 (20.0) 0 (0) 0.002 
ECG LVH 8 (26.7) 29 (54.7) 0.021 
ECG T wave inversion 22 (73.3) 13 (24.5) <0.001 
Atrial fibrillation 3 (10.0) 0 (0) 0.028 
QRS duration 109.5±12.17 89.8±10.26 <0.001 
Echo interventricular septum (diastole) 0.9 ± 0.2 1.2 ± 0.2 0.013 
Echo LV posterior wall (systole) 1.2 ± 0.3 1.4 ± 0.3 0.002 
Echo LV end-systolic diameter (diastole) 6.8 ± 0.7 3.5 ± 0.6 <0.001 
Echo LV end-diastolic dimension (diastole) 7.4 ± 1.1 5.1 ± 0.9 <0.001 
Echo LV ejection fraction 23.8 ± 8.3 49.9 ± 18.7 <0.001 
Echo LV fractional shortening 11.6 ± 4.1 26.2 ± 3.2 <0.001 
ECG, electrocardiographic; Echo, Echocardiographic; LV, left ventricle, left ventricular; LVH, left 
ventricular hypertrophy 
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Figure 6.2. Medication prescribed at last follow-up visit 
 
6.3.5. Survival analysis 
There were 5 deaths in PPCM patients during the 14 years of follow-up, while there were no deaths 
in the HHFP group (p = 0.005). A Kaplan-Meier analysis of survival stratified according to PPCM 
versus HHFP at last follow-up visit (p<0.001) is shown in Figure 6.3. Table 6.3 shows that chronic 
heart failure was more common in PPCM patients at the last follow-up visit (p<0.001). Similarly, 
intra-cardiac thrombus (p = 0.014) and development of pulmonary hypertension (p = 0.022) were 
commoner in PPCM patients. At the most recent hospital visit, 18 (72.0%) of PPCM patients were 
in NYHA functional class I and II and 7 (28.0%) were in functional class III and IV compared to 52 
(98.1%) of HHFP patients with class I and II symptoms and 1 (1.9%) with class III and IV 
symptoms (p<0.001). 
 
Figure 6.3 Kaplan-Meier survival plot for hypertensive heart failure of pregnancy and 
peripartum cardiomyopathy patients over 14 years 
 
Table 6.3. Survival and status at last follow-up for the PPCM and HHFP patients studied 
 
 PPCM 
(N=30) 
HHFP 
(N=53) 
P-value 
Median duration of follow-up 3.5 years 6 years 0.02 
Death 5 (16.7) 0 (0) 0.005 
Chronic heart failure 24 (80.0) 8 (15.1) <0.001 
Cardiac resynchronization therapy 1 (3.3) 0 (0) 0.361 
Intracardiac thrombus 5 (16.7) 0 (0) 0.014 
Stroke 2 (6.7) 0 (0) 0.128 
Pulmonary hypertension 4 (13.3) 1 (1.9) 0.022 
Heart transplantation 1 (3.3) 0 (0) 0.361 
NYHA FC at last visit 
          Class 1 and 2 
          Class 3 and 4 
 
18 (72.0) 
7 (28.0) 
 
52 (98.1) 
1 (1.9) 
 
<0.001 
NYHA FC, New York Heart Association Functional Class 
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6.4 Discussion 
We present the results of a case comparison study of the clinical features and outcome of 
pregnancy-associated heart failure with or without hypertension in patients with no history of 
structural heart disease and show that in our centre unexplained peripartum cardiomyopathy is 
exclusively a postpartum disease that is associated with distinct clinical features of heart muscle 
disease (such as left bundle branch block and atrial fibrillation), chronic heart failure, and a fatal 
outcome in a proportion of cases. By contrast, HHFP is predominantly an antepartum disease that 
presents mainly with pulmonary oedema, left ventricular hypertrophy (LVH), and a reversible form 
of heart failure in the overwhelming majority of cases. 
 
We have found that PPCM to be a postpartum condition, with 53% of PPCM patients presenting 
within the first month of the puerperium and the other 47% presenting within the subsequent four 
postpartum months, in contrast to HHFP, where 85% of patients presented with heart failure in the 
last month before delivery. Our findings are similar to those of another South African study which 
found that heart failure symptoms develop in the postpartum period in 100% of PPCM patients.25 
Summarising pooled data from 419 cases of PPCM, Lampert and Lang, demonstrated that 78% of 
PPCM cases developed symptoms in the first four months postpartum, while 9% had their onset of 
symptoms in the last antepartum month, and 13% either developed symptoms before one month 
antepartum or after four months postpartum.135  In the main, however, studies comprising a greater 
proportion of patients with preeclampsia have documented greater frequency of onset of PPCM in 
the last month of pregnancy.120,124 By comparison, studies with fewer cases of pregnancy-associated 
hypertension have reported a largely postpartum onset of PPCM.22,20,129,136 
 
A family history of hypertension was found more commonly in HHFP patients compared to PPCM 
patients; and in this study, a history of previous hypertension in pregnancy was present in a third of 
patients with HHFP and absent in those with PPCM. Genetic factors play a role in the development 
of pregnancy-induced hypertension (PIH), with both maternal and paternal genetic contributions 
being important.137,138 Genetic predisposition to PIH/preeclampsia is suggested by the observation 
that primigravid women with a family history of preeclampsia (i.e., affected mother or sister) have a 
2- to 5-fold increased risk of developing the disease than primigravid women without such a 
history.139 Furthermore, the spouse of men who are the product of a pregnancy complicated by 
preeclampsia are more likely to develop preeclampsia than spouses of men without such a 
history.140 
 
Features of congestive heart failure (pedal oedema, elevated jugular venous pressure, and basal 
rales) were found in up to 80% of PPCM patients, but only in 35.8% of HHFP patients at 
presentation. In contrast, isolated pulmonary oedema was one of the main clinical and radiologic 
findings in patients with HHFP in this study. The association of PIH/preeclampsia with isolated 
pulmonary oedema is well-established.141,142 Differences in clinical presentation between PPCM 
and HHFP may also be partly explained on the basis of volume overload in HHFP patients with 
systolic and diastolic dysfunction.143 The pathophysiology of pulmonary oedema in preeclampsia is 
unclear, but is presumed to be due to a combination of microangiopathy, capillary leak and 
sometimes iatrogenic fluid overload.144 PPCM, on the other hand, results from development of 
primary myocardial dysfunction leading to congestive heart failure,23,126 and has been shown 
recently, in a mouse model, to be associated with defective cathepsin-D mediated cleavage of 
prolactin into a 16-kDa form, which is both pro-apoptotic and anti-angiogenic.145 PPCM may also 
have genetic underpinnings, and recent reports have supported the contention that PPCM may be 
part familial dilated cardiomyopathy.66,105 
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Multiple differences were noted on ECG in the comparison between PPCM and HHFP. First, LVH 
was found to occur more commonly in HHFP than in PPCM. PIH represents a model of acute 
pressure overload that may induce dramatic changes in LV structure and function.146 Other 
important ECG findings from our study included the observation that QRS abnormalities, left atrial 
hypertrophy, left bundle branch block (LBBB), atrial fibrillation, non-specific T wave inversion and 
longer QRS duration occurred more frequently in patients with PPCM compared to those with 
HHFP. Similar findings have been reported previously: repolarisation changes have been reported 
in 47.3%147 and LBBB to occur in 10% of PPCM patients.148 Davidson and Parry found 
arrhythmias in 2%, and LBBB in 5% of patients with peripartum heart failure, while LVH was 
present in 26% and T wave changes found in 15%.149 In a study of 97 PPCM patients from South 
Africa, LVH was demonstrated in 66% and ST segment and T wave abnormalities noted in 96%.29 
These ECG changes are associated with increased cardiovascular morbidity and mortality in 
patients with impaired LV function, and QRS duration has been shown to be strongly associated 
with atrial fibrillation and adverse outcome in patients with cardiomyopathy.150 The 
electrocardiographic findings in our study may signify greater myocardial injury in patients with 
PPCM compared to those with HHFP. While the ECG of most women with PPCM is usually 
abnormal,22,151-154 there are no ECG changes that are sufficiently sensitive or specific for the 
diagnosis of PPCM,124 nor are there ECG characteristics that serve as a differentiator between 
PPCM and HHFP.  
 
A higher heart rate and blood pressure were found in patients with HHFP compared to those with 
PPCM. The finding of increased and/or highly variable pulse rates and elevated arterial pressures in 
PIH/preeclampsia has been described, and is thought to partly reflect disturbed neural control of 
heart rate and blood pressure, as a result of impaired sympathetic and parasympathetic nervous 
system activity in PIH.155 Maladaptation of the maternal cardiovascular system in PIH/preeclampsia 
is manifested as a lack of physiological decline in cardiovascular oscillations of heart rate and blood 
pressure.156   
 
On echocardiography, we found the interventricular septum (IVS) thickness and LV posterior free 
wall (LVPW) thickness to be increased in HHFP compared to PPCM, likely reflecting LV 
adaptation to increased wall stress from elevated blood pressure. Similarly, IVS and LVPW 
thickness were increased in PIH/preeclampsia patients compared with normal controls.157 PIH was 
associated with an abnormal LV geometric pattern in 62% of 106 patients studied, of which 42% 
had eccentric hypertrophy, 17% had concentric remodeling, and 5% had concentric hypertrophy.158 
Again, likely reflecting greater myocardial injury, the LVEF and LV fractional shortening were 
lower in PPCM patients and were associated with increased LV dimensions in systole and diastole. 
Similarly, demonstrating impaired LV function (i.e., depressed LVEF, LV cardiac output and stroke 
volume) and increased LV dimensions have been reported in PPCM by many authors.22,127-9 
Furthermore, the LVEF and LVEDD have been correlated with outcome in PPCM,123,159 but not in 
this study. 
 
Finally, we showed that morbidity and mortality was higher in PPCM, with lack of full recovery of 
cardiac function (average LVEF 23.8% at diagnosis and 31.3% at last follow-up), compared to 
HHFP patients (average LVEF 49.9% at diagnosis and 68.2% at last follow-up). Similar findings 
have recently been made by Kamiya and colleagues who examined the clinical profile of Japanese 
PPCM patients with and without gestational hypertension and found that patients with pregnancy-
associated hypertension diagnosed with PPCM had a shorter hospitalisation and higher LVEF at last 
follow-up when compared to the PPCM patients without hypertension.159 The mortality for PPCM 
of 17% over a median of 3.5 years of follow-up is similar to that seen in other countries such as 
Haiti and Turkey, but much higher than the United States.134 Chronic heart failure, intra-cardiac 
thrombus, thromboembolic phenomena and pulmonary hypertension occurred with greater 
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frequency in patients diagnosed with PPCM. These grave sequelae have been previously reported 
on in PPCM, and shown to be associated with increased mortality.123,126,128,160 However, the 
seriousness of HHFP should not be under-estimated: a recent report on maternal deaths from South 
Africa showed that preeclampsia/eclampsia and proteinuric hypertension accounted for 83.1% of all 
PIH-related deaths, and that HHFP was the cause of death in 22.8% of PIH-related deaths in the 
same period.161 
 
The data from this sub-study show that there are significant differences in the time of onset of heart 
failure, clinical characteristics, and outcomes of patients with HHFP compared to those with truly 
unexplained PPCM. Hence, these data support the proposal that a history or presence of 
hypertension in pregnancy should exclude the diagnosis of PPCM, as the two appear to be distinct 
clinical conditions.22,23,69 However, this study has a number of limitations including small sample 
size, being from a single centre, differences in follow-up duration between HHFP and PPCM 
patients, lack of repeat echocardiography in the majority of HHFP patients at follow-up and the lack 
of information about repeat pregnancies and the potential for confusion between the symptoms of 
heart failure and the often similar symptoms of normal pregnancy. It is also important to highlight 
that, by its very nature, a specialist clinic in a tertiary referral center has a selection bias for the 
cases that develop chronic PPCM, and may miss cases that demise acutely. Finally, we 
acknowledge that using strict cut-offs for case definition of PPCM may have led to an 
underestimate of its prevalence in our setting. 
 
Despite these limitations, this work may contribute to the clarification of the case definition of 
PPCM by excluding patients with any form of hypertension in this group. We show that HHFP is 
predominantly an antepartum disease that presents mainly with pulmonary oedema, LVH, and a 
reversible form of heart failure in the overwhelming majority of cases. By contrast, at our centre, 
unexplained PPCM is exclusively a postpartum disease that is associated with distinct clinical 
features of heart muscle disease (such as LBBB and atrial fibrillation), chronic heart failure, and a 
fatal outcome in a proportion of cases. Large prospective multicenter studies of peripartum heart 
failure with and without hypertension are required to confirm the findings of this study.  
 
6.5 Conclusions 
In this case comparison study of the clinical features and outcome of pregnancy-associated heart 
failure with or without hypertension in patients with no history of structural heart disease we found 
that unexplained peripartum cardiomyopathy is exclusively a postpartum disease that is associated 
with distinct clinical features of heart muscle disease (such as LBBB and atrial fibrillation), chronic 
heart failure, and a fatal outcome in some cases. By contrast, HHFP is predominantly an antepartum 
disease that presents mainly with pulmonary oedema, LVH, and a reversible form of heart failure in 
the overwhelming majority of cases.
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Chapter 7 
Clinical features, spectrum of causal genetic mutations, and 
outcome of hypertrophic cardiomyopathy in South Africans 
 
 
 
7.1     Introduction 
Hypertrophic cardiomyopathy (HCM) is defined by the presence of myocardial hypertrophy in the 
absence of haemodynamic stresses sufficient to account for the degree of hypertrophy  (e.g., arterial 
hypertension and aortic stenosis) and without other secondary causes of cardiac hypertrophy such as 
amyloidosis and glycogen storage disease.8 HCM was historically thought to be rare amongst 
Africans.32 This impression was reinforced by a study which found HCM to occur in 0.2% of 6680 
unselected echocardiograms performed in Tanzania.31 However, recent echocardiographic studies 
from the continent have dispelled that myth.34 For example, in Ghana, HCM has been reported to be 
the third commonest cardiomyopathy after DCM and endomyocardial fibrosis (EMF).35 Similarly, 
in Ethiopia, HCM accounts for 34% of all cardiomyopathies diagnosed on echocardiography.36 
However, there is a dearth of information on the clinical features, genetics and outcome of HCM 
from the African continent, with a few publications reporting on HCM-causing mutations in South 
Africans of North-European descent and mixed ancestry.162-165 To date, there are no data on the 
genetics of HCM in black Africans. 
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HCM is a diverse disease with variable phenotypic expression; a substantial proportion of patients 
live a normal life with minimal risk of sudden cardiac death.166 However, some patients with or 
without symptoms may die suddenly even without clinical features of severe LVH.164 The pattern of 
LVH in HCM is variable and associated with differences in morbidity and mortality. For instance, 
apical HCM in the Japanese and North American populations is associated with a benign 
outcome.167 The clinical pattern and outcome of HCM in Africans is not known. The aim of this 
sub-study was to delineate the clinical features, spectrum of disease causing mutations, and 
outcome of HCM in African patients. 
 
7.2 Methods 
7.2.1. Study design 
Consecutive patients diagnosed with HCM at the Cardiac Clinic, GSH, Cape Town, South Africa 
were prospectively enrolled into a longitudinal cohort study of familial cardiomyopathy, from 
February 1, 1996 to August 31, 2012. The diagnosis of HCM was based on the presence of a 
hypertrophied, non-dilated LV in the absence of other diseases capable of producing the degree of 
observed LVH (i.e., LV wall thickness >15mm on echocardiography).168 Clinical data were 
collected at 6 monthly visits during the study period.  
 
7.2.2. Measurements and data collection 
All patients had comprehensive clinical assessment, complemented by chest radiography, 
electrocardiography, detailed two-dimensional and Doppler colour-flow echocardiography and 
cardiac catheterisation, when appropriate. The primary imaging modality used for diagnosis in all 
patients was transthoracic two-dimensional and Doppler echocardiography. Patients found to have 
outflow tract gradients below 40 mmHg underwent Valsalva maneuver. Patients with 
cardiovascular risk factors, angina or over 40 years old frequently underwent coronary angiography, 
at the discretion of the attending clinician. A comprehensive database that incorporated patient 
demographic details, medical history, co-morbidity, medical therapy, clinical, electrographic and 
echocardiographic details was utilised. Normal values for echocardiographic measurement were 
based on age and body-surface area as described by Lauer et al.169  
 
7.2.3. Genotyping 
Peripheral blood was collected from HCM probands for DNA extraction using standard methods. 
Mutation screening was undertaken by pyrosequencing of the coding regions and exon/intron 
boundaries of the following 15 genes that are associated with HCM: cardiac myosin-binding protein 
C (MYBPC3), cardiac β-myosin heavy chain (MYH7), cardiac troponin T type 2 (TNNT2), cardiac 
troponin I type 3 (TNNI3), regulatory light chain of myosin (MYL2), essential light chain of 
myosin (MYL3), tropomyosin 1 (TPM1), phospholamban (PLN), α-actin (ACTC1), cysteine and 
glycine-rich protein 3 (CSRP3), AMP-activated protein kinase  (PRKAG2), α-galactosidase (GLA), 
four-and-a-half LIM domains 1 (FHL1), lamin A/C (LMNA) and lysosome-associated membrane 
protein 2 (LAMP2) (Table S1).53 
 
Exons and intron/exon boundaries (± 10 base pairs) of the 15 cardiomyopathy related genes were 
amplified by microdroplet polymerase chain reaction (PCR) using RDT 1000 technology (Rain 
Dance Technologies, Billerica, MA 01821, United States). Libraries were prepared using the Rapid 
Library 454 FLX protocol, which included adding molecular identifiers to each sample. Samples 
were pooled and then sequenced using the Roche 454 FLX next-generation sequencing platform.  
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Samples were processed and analysed using NextGENe version 2.2.0 (SoftGenetics).  Prior to 
analysis, reads were trimmed and low quality reads removed. Reads were aligned to .gbk files and 
variants seen in <20% annotated. Variants were filtered taking into account coverage, read balance, 
allele balance and homopolymers. Samples with coverage below 10 were considered failures. 
Unclassified variants were Sanger sequenced to confirm their presence; known polymorphisms 
were not Sanger sequenced. 
 
The Cape Town population controls were used to determine the population frequencies of all novel 
variants identified in the 15 genes. One hundred and ninety five (n=195) anonymous blood donors 
from the Western Province Blood Transfusion Service (WPBTS) provided   consent for blood 
samples to be taken for DNA extraction. The control DNA consisted of samples from 95 persons of 
mixed ancestry, 50 black Africans and 50 white South Africans. 
 
7.2.4. Ethical considerations 
The study was designed in keeping with the principles of the Helsinki Declaration, and was 
approved by the University of Cape Town Human Research Ethics Committee. All participants 
gave informed, written consent to participate in the study.  
 
7.2.5. Statistical analysis 
Simple descriptive statistics were used for data interpretation and to draw inferences about the 
population of patients studied. Results of continuous variables are given as means ± SD. 
Categorical variables are represented as number and percentage. Pearson’s chi-square or Fisher’s 
exact test was used to compare the relative frequency of characteristics between individuals. All P 
values were two-sided; and P values ≥ 0.05 were considered not to indicate statistical significance. 
Survival analysis testing between groups was compared using log-rank testing, and the Kaplan-
Meier survival curves were constructed using the product-limit method. Age-, gender- and race-
adjusted survival curves for the general South African population were derived and compared with 
the Kaplan-Meier survival rates for the patients with HCM. Analysis included univariate and 
multivariate regression analysis, with a focus on mortality rather than time to death, thus justifying 
the use of Cox’s proportional hazards model rather logistic regression analysis.  
 
7.3 Results 
7.3.1. Clinical characteristics 
The study cohort comprised 43 patients with HCM. The clinical characteristics and co-morbid 
status of the study population at the initial evaluation are shown in Table 7.1 and compared to 
cohorts from North America, Taiwan and Saudi Arabia. The mean age of HCM patients studied was 
38.5 ± 14.3 years; 25 (58.1%) were male. Thirteen (30.2%) were black Africans, and the majority 
(62.8%) were of mixed ancestry. Twenty six (60.5%) had first degree relatives with HCM and 5 
(11.6%) had a family history of sudden cardiac death (SCD) in a first degree relative. Symptoms of 
palpitations (79.1%), angina (65.1%), fatigue (58.1%), and effort-related breathlessness (55.8%) 
were frequently reported by the patients. Ten (23.3%) had a New York Heart Association (NYHA) 
functional capacity of class III at the initial assessment. An ejection systolic murmur was reported 
in 18 (41.9%) of patients.  
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Table 7.1. Demographic, clinical, electrocardiographic and echocardiographic features at 
presentation in patients with hypertrophic cardiomyopathy compared to three large 
international, contemporary reports from North America, Taiwan and Saudi Arabia 
 
Characteristic South 
Africa 
(n=43) 
North 
America 
(n=277) 
Taiwan 
(n=163) 
Saudi 
Arabia 
(n=69) 
Medical history 
Age at diagnosis, years 38.5 ± 14.3 47 ± 22 60.9 ± 12.1 42 ± 16 
Males 25 (58) 152 (55) 84 (52) 43 (71) 
Ethnicity (%) 
          Black/African 
          White/Caucasian 
          Coloured/Mixed ancestry 
          Indian ancestry 
          Taiwanese 
          Arab 
 
13 (30) 
2 (5) 
27 (63) 
1 (2) 
 
 
277 (100) 
 
 
 
 
 
 
163 (100) 
 
 
 
 
 
 
69 (100) 
First degree relative with HCM 26 (61) 21 (8) ‒ 2 (5) 
Second degree relative with HCM 7 (16) ‒ ‒ ‒ 
Has family history of SCD 5 (12) ‒ ‒ 4 (9) 
NYHA functional class 
          Class 1 and 2 
          Class 3 and 4 
 
33 (77) 
10 (23) 
 
‒ 
 
‒ 
 
‒ 
Symptoms 
          Fatigue 
          Dyspnoea 
          Palpitations 
          Angina 
          Presyncope/Syncope 
 
25 (58) 
24 (56) 
34 (79) 
28 (65) 
12 (28) 
174 (63)  
‒ 
121 (74) 
28 (17) 
111 (68) 
20 (12) 
 
‒ 
31 (65) 
5 (7) 
‒ 
2 (4) 
Smoking 19 (31) ‒ ‒ ‒ 
Hypertension 12 (28) ‒ 28 (17) ‒ 
Diabetes 0 (0) ‒ 29 (18) ‒ 
Alcohol consumption 9 (21) ‒ ‒ ‒ 
Dyslipidaemia 6 (14) ‒ ‒ ‒ 
Coronary artery disease 3 (7) ‒ 29 (18) ‒ 
COPD 2 (5) ‒ ‒ ‒ 
HIV infection 2 (5) ‒ ‒ ‒ 
Medical examination 
Heart rate 71.3 ± 12.7 ‒ ‒ ‒ 
BPsys 125.8 ± 19.2 ‒ ‒ ‒ 
BPdia 75.8 ± 11.3 ‒ ‒ ‒ 
Pedal oedema 5 (11.6) ‒ ‒ ‒ 
Ejection systolic murmur 18 (41.9) ‒ ‒ ‒ 
Electrocardiographic findings 
Sinus rhythm 39 (90.7) ‒ ‒ ‒ 
Atrial fibrillation 4 (9.3) ‒ 34 (21) ‒ 
QRS abnormalities present 12 (28) ‒ ‒ ‒ 
Voltage criteria for LVH 22 (51) ‒ 137 (84) 60 (87) 
Presence of pathological Q waves 12 (28) ‒ ‒ ‒ 
T wave inversion 34 (79) ‒ 108 (66) ‒ 
Left atrial hypertrophy 10 (23) ‒ ‒ ‒ 
LBBB 4 (9) ‒ ‒ ‒ 
RBBB 2 (5) ‒ ‒ ‒ 
PR prolongation 2 (5) ‒ ‒ ‒ 
Echocardiographic findings 
LVEDD (cm) 4.1 ± 0.8 ‒ 4.5 ± 0.5 ‒ 
LVESD (cm) 2.7 ± 0.6 ‒ 2.4 ± 0.4 ‒ 
IVSdia (cm) 1.9 ± 0.7 2.2* 1.9 ± 0.4 ‒2.1 ± 0.7 
IVSsys (cm) 2.1 ± 0.7 ‒ ‒ ‒ 
LVPFWdia (cm) 1.2 ± 0.4 ‒ 1.1 ± 0.3 1.3 ± 0.4 
LVEF (%) 71.5 ± 8.3 ‒ ‒ 68 ± 13 
Left atrial size (cm) 3.5 ± 0.8 ‒ 3.8 ± 0.7 ‒ 
SAM  9 (21) ‒ 80 (49) 39 (57) 
LVOT obstruction 12 (28) ‒ 78 (48) 28 (41) 
E/A ratio 1.2 ± 0.4 ‒ ‒ 1.5 (0.9-2.1) 
Pattern of hypertrophy 
       Sigmoid 
       Catenoid 
       Neutral 
       Apical 
 
13 (30) 
23 (53) 
6 (14) 
1 (2) 
 
75 (27) 
92 (33) 
65 (23) 
5 (2) 
 
‒ 
 
8 (12) 
29 (42) 
25 (36) 
7 (10) 
All results are means ± standard deviation, unless otherwise indicated. 
*No standard deviation given. 
BPdia, diastolic blood pressure; BPsys, systolic blood pressure; COPD, chronic obstructive 
pulmonary disease; E/A, ratio of early (E) to late (A) ventricular filling velocities on Doppler 
echocardiography; IVSdia, interventricular septal thickness in diastole; IVSsys, interventricular septal 
thickness in systole; HCM, hypertrophic cardiomyopathy; HIV, human immunodeficiency virus; 
LBBB, left bundle brunch block morphology on electrocardiography; LVEDD, left ventricular end-
diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic 
dimension; LVH, left ventricular hypertrophy; LVPFWdia, left ventricular posterior free wall 
thickness in diastole; LVOT, left ventricular outflow tract; NYHA, New York Heart Association 
functional classification for severity of breathlessness; RBBB, right bundle brunch block 
morphology on electrocardiography; SAM, systolic anterior motion of the anterior mitral valve 
leaflet; SCD, sudden cardiac death.  
 
7.3.2 Electrocardiographic and echocardiographic findings 
The electrocardiographic and echocardiographic characteristics of the study population are 
shown in Table 7.1. Four (9.3%) of the HCM patients had atrial fibrillation at diagnosis. On 
echocardiography, the mean LV septal thickness in diastole, LV ejection fraction (LVEF) and 
left atrial diameter were 1.9 ± 0.7cm, 71.5 ± 8.3% and 3.5 ± 0.8cm, respectively. LV outflow 
tract (LVOT) obstruction, with a resting gradient of greater than 10 mmHg, was found in 12 
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(27.9%) patients. Evidence of diastolic dysfunction was present in the majority of patients, 
and the mean E/A ratio was 1.2 ± 0.4.  
 
7.3.3. Spectrum of mutations that cause HCM in South Africans 
Of the 43 patients diagnosed with HCM, 42 were screened for the common founder mutations 
previously described in the South African population, and all 42 were found to be negative for 
these variants.165 Further molecular genotypic analysis was undertaken in 35 of these HCM 
patients for 15 cardiomyopathy-associated genes. Of these 35 probands, mutation screening 
yielded disease-causing mutations in 10 unrelated individuals (28.6%) (Table 7.2). The 
disease-causing mutations were found in two out of the 15 genes screened, with the majority 
in MYH7 (n = 6 probands; 60%) and the rest in MYBPC3 (n = 4 probands; 40%). Two of the 
MYH7 mutations were novel and disease-causing mutations were found in all ethnic groups 
tested. No single disease-causing mutation occurred in more than one study subject.  
 
There were three genetic variants of unknown significance that were found in MYBPC3 
which were not observed in 195 population controls: c.1224-19G>A, c.1790+5G>A, and 
c.133G>A. In addition, a large number of known polymorphisms were found in 16 probands 
in MYBPC3 (tmp_esp_11_47355301, rs113941605 and rs113658284), MYH7 (rs149439730, 
rs45523835, rs145738465, rs202205780, rs61737803, rs146858930, rs36211714, 
rs45501694, and rs111626355), TNNT2 (rs113471285, and rs115805892), TPM1 
(tmp_esp_15_63356347), MYL3 (rs199474709), CSRP3 (rs112848043), FHL1 
(rs182106777), PRKAG2 (rs116605521, and rs113234987), GLA (rs151195362), and LMNA 
(rs12117552, and rs117939448). Two novel single nucleotide polymorphisms were found in 
MYH7 (c.1368C>T) and PRKAG2 (c.828C>A) in two different probands. 
Table 7.2. Disease causing mutations found in 10 unrelated index cases with hypertrophic 
cardiomyopathy 
Index case 
ID 
Ethnicity Reported 
previously
? 
Gene Exon Nucleotide 
and Amino 
acid change 
Type of 
mutation 
Reference 
HCM1.1 Indian Yes MYH7 5 c.611G>A 
(p.R204H) 
Missense Richard et al 
200318 
HCM4.1 Mixed 
ancestry 
No MYH7 20 c.2282C>A 
(p.T761N) 
Missense Novel 
HCM7.1 Mixed 
ancestry 
Yes MYH7 31 c.4258C>T 
(p.R1420W) 
Missense Zou et al 
201323 
HCM11.1 Mixed 
ancestry 
Yes MYBP
C3 
12 c.1000G>A 
(p.E334K) 
Missense Bahrudin et al 
200824 
HCM14.1 European No MYH7 20 c.2167C>T 
(p.R723C) 
Missense Novel 
HCM16.1 European Yes MYH7 9 c.746G>A 
(p.R249Q) 
Missense Zou et al 
201323 
HCM21.1 Black 
African 
Yes MYBP
C3 
6 c.772G>A 
(p.E258K) 
Missense Andersen et al 
200425 
HCM33.1 Mixed 
ancestry 
Yes MYBP
C3 
5 c.530G>A 
(p.R177H) 
Missense University of 
Stellenbosch 
thesis26 
HCM34.1 Black 
African 
Yes MYH7 14 c.1357C>T 
(p.R453C) 
Missense Zou et al 
201323 
HCM38.1 Black 
African 
Yes MYBP
C3 
15 c.1246G>A 
(p.G416S) 
Missense Tanjore et al 
200827 
HCM, hypertrophic cardiomyopathy; MYBPC3, cardiac myosin-binding protein C; MYH7, cardiac 
β-myosin heavy chain. 
 
The total number of variants in the 15 genes per HCM patients (regardless of whether it was 
disease-causing or not) ranged from 6 to 20 (mean: 12.8, SD 3.2; median 12). The patient who 
died had a higher number of variants (14.8±3.9) compared to survivors (12.5±3.1), although 
this difference was not statistically significant (P=0.47). 
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7.3.4. Outcome of HCM in South Africans 
The mean duration of follow-up was 9.1 ± 3.4 years. Of the 43 patients studied, 8 died during the 
period of follow-up. The overall Kaplan-Meier survival estimate is shown in Fig. 7.1A; the 
cumulative proportion of patients who survived to 10 years was 74%. Complications of chronic 
heart failure, atrial fibrillation, stroke and evolution to dilated cardiomyopathy with systolic 
dysfunction were observed in 11 (25.6%), 8 (18.6%), 4 (9.3%), and 4 (9.3%), respectively. 
Therapeutic interventions including surgical myomectomy, alcohol septal ablation and orthotopic 
heart transplantation were performed on 3 (7.0%), 1 (2.3%) and 1 (2.3%) patients, respectively. At 
the last visit, 12 (27.9%) reported NYHA functional class III and IV performance status (Table 7.3). 
The most frequently prescribed drugs were beta-blockers and calcium channel blockers, used by 33 
(76.7%) and 17 (39.5%) patients, respectively (Table 7.4).  
 
Cox’s proportional hazards regression showed that survival was predicted by NYHA functional 
class at last visit (P=0.026), but not by presence of a disease-causing mutation (P=0.474), as shown 
in Figures 7.1B and 7.1C, respectively. Survival in this cohort was similar to that of an age- and 
sex-matched general South African population (Figure 7.1D). 
 
The presence of chronic heart failure (hazard ration (HR) 4.4, CI 1.0 – 18.3; p=0.044) and NYHA 
functional class at last visit (HR 6.2, CI 1.2 – 30.6; p=0.026) were found to be predictors of 
mortality on univariate regression analysis. On multivariable analysis, both chronic heart failure and 
NYHA functional class were not significant as predictors of mortality, as they may be proxies for 
LV ejection fraction (Table 7.5).  
Table 7.3. Follow-up and outcome data 
 
Mean duration of follow-up (years ± SD) 9.1 ± 3.4 
Total number of mutations per person  12.8 ± (3.2) 
Follow-up observation 
          Regular 
          Lost to follow-up 
 
37 (86.0) 
6 (14.0) 
Death 8 (18.6) 
Chronic heart failure 11 (25.6) 
ICD insertion 0 (0) 
PPM insertion 0 (0) 
CRT/Biventricular pacing 0 (0) 
Loop recorder 6 (14.0) 
Arrhythmia present 
          No arrhythmia 
          Atrial fibrillation 
         Atrial flutter 
         Ventricular tachycardia 
 
32 (74.4) 
8 (18.6) 
1 (2.3) 
2 (4.7) 
Myomectomy 3 (7.0) 
Alcohol septal ablation 1 (2.3) 
Evolution to DCM 4 (9.3) 
Orthotopic heart transplantation 1 (2.3) 
NYHA FC at last visit 
          Class 1 and 2 
          Class 3 and 4 
 
31 (72.1) 
12 (27.9) 
Stroke 4 (9.3) 
All values are number (percentage), unless otherwise stated.  
ICD, implantable cardioverter-defibrillator; PPM, permanent pacemaker; CRT, cardiac 
resynchronisation therapy; DCM, dilated cardiomyopathy; NYHA, New York Heart 
Association functional classification for evaluation of severity of dyspnea.  
   
Table 7.4. Medical therapy at follow-up 
B-blocker 33 (76.7) 
Calcium channel blocker 17 (39.5) 
Warfarin 12 (27.9) 
ACE-I or ARB 9 (20.9) 
Furosemide 8 (18.6) 
Aspirin 8 (18.6) 
Disopyramide 4 (9.3) 
Spironolactone 4 (9.3) 
Amiodarone 3 (7.0) 
Digoxin 2 (4.7) 
Nitrates 1 (2.3) 
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; B-blocker, 
beta blocker. 
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Figure 7.1. Kaplan-Meier survival estimates in hypertrophic cardiomyopathy 
A. Kaplan-Meier plot showing the survival of HCM patients; B. Kaplan-Meier plot showing the 
survival of HCM patients when stratified by NYHA functional class; C. Kaplan-Meier plot showing 
the survival of HCM patients when stratified by presence or absence of HCM-causing mutation(s); 
and D. Kaplan-Meier plot showing the survival of HCM patients when compared to age-, sex- and 
race-matched members of the South African population 
Table 7.5. Cox’s proportional hazards regression model analysis of predictors of mortality in 
hypertrophic cardiomyopathy 
 
Univariate Cox Regression 
 Hazard ratio (95% CI) P-value 
Age at diagnosis 1.0 (1.0 – 1.1) 0.561 
Mutation positive 1.8 (0.4 – 8.9) 0.474 
Sarcomeric mutations 1.3 (0.5 – 3.5) 0.585 
Total number of mutations per person 1.12 (0.91 – 1.3) 0.412 
IVS 1.6 (0.8 – 3.4) 0.169 
LVEF 1.1 (1.0 – 1.2) 0.060 
Family history of SCD 0.8 (0.1 – 6.6) 0.840 
E/A ratio 2.0 (0.4 – 10.0) 0.370 
Loop recorder 3.5 (0.8 – 14.6) 0.088 
Chronic heart failure 4.4 (1.0 – 18.3) 0.044 
NYHA functional class at last visit 6.2 (1.2 – 30.6) 0.026 
   
Multivariate Cox regression 
 Hazard ratio (95% CI) P-value 
LVEF  1.1 (1.0 – 1.2) 0.100 
Loop recorder 0.8 (0.1 – 5.3) 0.828 
Chronic heart failure 1.6 (0.2 – 16.2) 0.684 
NYHA functional class at last visit 4.2 (0.4 – 41.3) 0.218 
E/A, ratio of early (E) to late (A) ventricular filling velocities on Doppler echocardiography; IVS, 
interventricular septal thickness in diastole; HCM, hypertrophic cardiomyopathy; LVEF, left 
ventricular ejection fraction; NYHA, New York Heart Association functional classification for 
severity of breathlessness; SCD, sudden cardiac death. In the univariate and multivariate regression 
analysis, NYHA was correlated as a binary variable (NYHA FC I-II vs. NYHA FC III-IV). 
 
 
 
7.4 Discussion 
To our knowledge this is the first prospective study of the clinical profile, spectrum of disease-
causing gene mutations and outcome in HCM from the African continent, including black Africans. 
Age at onset of symptoms (38.5 ± 14.3 years), male preponderance (58%), and major symptoms 
were similar to those reported in North American, Middle Eastern, and Eastern series (Table 
1).166,170,171 Nearly 30% of patients bear mutations in the MYH7 and MYBPC3 genes which are the 
commonest genetic causes of HCM.53 Whilst the annual mortality rate of 2.9% was high and the 
overall survival of 74% at 10 years is low compared to other series of patients with HCM,166 the 
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survival rate was comparable to age- and sex-matched members of the South African population. 
Survival was predicted by New York Heart Association (NYHA) functional class at last visit. 
 
We have found that HCM occurs predominantly in men, with a young age of onset, including black 
Africans; and with a positive family history of HCM in the majority. Fatigue, breathlessness and 
palpitations were the commonest symptoms. Atrial fibrillation was found in 9%, LVOT obstruction 
in 28%, and diastolic dysfunction in most. In a study of the natural history of HCM in non-
hospitalised Americans, Maron and others found that 55% of patients were men and the mean age 
was 47 years, and cardiac symptoms were present in 63% of patients.166 Similarly, in a study from 
Taiwan, Lee and colleagues found 52% HCM patients to be male, and that men had a younger age 
of onset of HCM compared to women;170 in this study the prevalence of apical HCM was three 
times higher in men, and interestingly, men had lower prevalence of LVOT obstruction. Thirty-six 
percent of Taiwanese HCM patients had pulmonary oedema or paroxysmal atrial fibrillation. More 
recently, in the first report on the clinical characteristics of HCM in Saudi Arabia, Ahmed and 
coauthors found the population of HCM patients to be 71% male, and with a mean age of 42 
years.171 Dyspnoea and palpitations were the commonest symptoms, and LVOT obstruction was 
found in 28%.  
 
To date, over 1400 mutations have been reported to cause HCM in genes encoding eight sarcomere 
proteins: beta-myosin heavy chain (MYH7), cardiac myosin-binding protein C (MYPBC3), cardiac 
troponin T (TNNT2), cardiac troponin I (TNNI3), cardiac actin (ACTC), alpha-tropomyosin 
(TPM1), essential light chain of myosin (MYL3) and regulatory light chain of myosin (MYL2).53,172 
Mutations in MYH7 and MYPBC3 occur most often, and account for approximately 50% of HCM 
cases,173,174 while mutations in TNNT2, TNNI3, ACTC, TPM1, MYL3 and MYL2 collectively 
account for less than 20% of HCM cases.175 In our study, mutations in MYH7 and MYPBC3 were 
the commonest causes of HCM.  
 
Moolman-Smook and colleagues have done pioneering work on the genetics of HCM in two South 
African subpopulations: those of European descent and those of mixed ancestry, and have 
previously reported on common HCM-causing mutations that arose independently and 
demonstrated clear founder effects in the South African population. These mutations included the 
MYH7 Ala797Thr (25% prevalence),163 TNNT2 Arg92Trp (15%),164 MYH7 Arg403Trp (5%),162 
MYH7 Arg717Gln and the MYH7 Glu499Lys176 mutations, which collectively accounted for 
47.5% of cases of HCM from the Eastern and Western Cape provinces of South Africa. To save 
money and to improve efficiency, a strategy was proposed to first screen for these 5 founder 
mutations before undertaking an extensive molecular genetic screening for other HCM mutations in 
South Africa.165 However, in our study of 42 South African HCM patients, these founder mutations 
were absent. 
 
The mutation yield of screening 15 sarcomeric and non-sarcomeric genes that are associated with 
HCM was relatively low in this study. Disease-causing mutations in any one of sarcomeric protein 
genes are found in up to two thirds of patients with HCM, and the yield of screening associated 
causal genes ranges from 40-70%.53 The indications for molecular genetic testing in 
cardiomyopathy vary according to the yield of molecular testing, the cost of the molecular analyses, 
and impact of genetic testing on the medical management of the individual and the family. Given 
the relatively low yield of screening in this study, molecular genetic testing in Africans with HCM 
should probably not be carried out routinely as yet until studies of the full spectrum of causal 
mutations and of the impact of genetic testing on outcome are available. 
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In our study, the mean duration of follow-up was 9.1 years with an annual mortality rate of 2.9%; 
and complications included heart failure, atrial fibrillation, stroke and evolution to DCM. 
Myomectomy, alcohol septal ablation and heart transplantation were performed in a small number 
of patients; however no implantable-cardioverter defibrillators (ICDs) were used. The high rates of 
mortality observed in our study may reflect, in part, the higher mortality of the South African 
population as well as the skewed nature of tertiary centre experience with many symptomatic 
patients. In the US, HCM was found to have an annual mortality rate of 1.3%, and to be associated 
with stroke, atrial fibrillation, sudden cardiac death, congestive heart failure and need for heart 
transplantation.166 In Taiwan, HCM was reported to have an annual mortality rate of 0.8%, and 
mortality to be predicted by LVOT obstruction, atrial fibrillation and female gender.170 In Saudi 
Arabia, HCM had an annual mortality rate of 0.7%, with 5 ICDs inserted over 7 years of follow-up 
and a single patient progressing to end-stage dilated cardiomyopathy.171 
 
This sub-study has a number of important limitations. First, the small sample size is a major 
weakness. This may account for the failure to detect the effect of known predictors of mortality in 
HCM, such as history of syncope and magnitude of LVH. Second, we screened for 15 genes that 
are commonly associated with HCM. However, there are several important HCM-causing mutations 
in other genes that were not included in our genetic panel, such as titin (TTN), myosin heavy chain 
gene (MYH6) and cardiac troponin C (TNNC). Therefore, there is a need for larger prospective 
studies of HCM in Africa that encompass all the important genetic causes of the disease. 
 
7.5 Conclusions 
We report on the first prospective investigation of the clinical characteristics, genetics, and outcome 
of HCM in Africans. We found HCM to occur most in men, and to have a young age of onset. 
Major symptoms and complications were similar to those reported in North American, Middle 
Eastern, and Asian studies. Known and novel disease-causing mutations were identified in the 
MYH7 and MYBPC3 genes with a lower yield of mutation screening of about 30% compared to the 
expected 40-70% elsewhere. The mortality in this contemporary African HCM series was, however, 
higher than reported elsewhere, although comparable to age- and sex-matched members of the 
South African population. Survival was predicted by New York Heart Association (NYHA) 
functional class at last visit. 
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Chapter 8 
 
 
Genotype: phenotype correlations in hypertrophic 
cardiomyopathy patients with the three known South African 
founder mutations: a cardiovascular magnetic resonance study 
 
 
 
8.1 Introduction 
Hypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere characterised by 
ventricular myocardial hypertrophy, myocyte disarray and cardiac fibrosis, in the context of a non-
dilated LV,8 and in the absence of increased external load.76,177 HCM is caused by over 1400 
mutations found in at least 20 causal genes that encode sarcomeric and calcium-handling proteins, 
as well as in genes that encode other proteins (e.g. Z-disc proteins) that interact with sarcomeric 
proteins.173,174 Furthermore, mitochondrial mutations, lysosomal storage diseases, as well as 
infiltrative cardiomyopathies may be HCM phenocopies;175 however the molecular aetiologies of 
these disorders are distinct from HCM. 
 
The known HCM-causing genes are useful for (1) effective gene-based diagnosis of HCM, (2) 
accurate assessment of disease risk in family members, and (3) providing insight into likely clinical 
course of HCM in affected individuals.173 Several studies have attempted to correlate the clinical 
features and course of HCM to a specific causal mutation; and such genotype: phenotype studies 
have implied that the causal allele is responsible, in part, for the variability observed in HCM 
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phenotype. Specific mutations have been linked with extensive left ventricular hypertrophy (LVH), 
mid-cavity obstruction, apical hypertrophy, age of onset, risk of sudden cardiac death (SCD), 
incidence of congestive cardiac failure, risk of progression to cardiac dilation and conduction 
disease.178-187 However, none of these mutations have been exclusively associated with the 
proposed HCM phenotypes. Furthermore, the pathophysiological pathway between genetic 
mutation and resulting clinical HCM phenotype is incompletely understood. 
 
There is significant overlap between the clinical phenotype of unexplained LVH and HCM-causing 
mutations, making the utility of clinical findings to accurately predict pathophysiologic 
involvement of a particular gene difficult. Moreover, genotypic: phenotypic correlations have been 
limited by small numbers of genotyped HCM patients, small sizes of families included in studies, 
differing age distributions of mutation-carriers within families, low individual frequency of HCM-
causing gene mutations, variable clinical expression within and between families, and poor 
understanding of the genetic heterogeneity that modifiers such as background genotypes, gender 
and environment have on phenotypic expression.188-190 Despite all these complexities, it is generally 
recognised that the clinical course of HCM tends to be more severe in those with an identified 
causative genetic mutation and in those with multiple HCM-causing mutations.191  
 
Extensive genetic studies in South African HCM patients have identified three unique HCM-
founder alleles: the A797T mutation and the R403W mutation in the beta-myosin heavy chain 
(MHY7) gene, and the R92W mutation in the cardiac troponin T (TNNT2) gene.162-165,192 Haplotype 
analysis has confirmed that these mutations are identical-by-descent, indicating that individuals 
bearing the same mutation are ancestrally related.165 The purpose of this sub-study was to 
investigate whether there were any correlations between genotype and phenotypic manifestations, 
based on cardiovascular magnetic resonance (CMR) features. 
 8.2 Methods 
8.2.1. Study design 
The study was designed as a cross-sectional study of the relation of CMR phenotypic characteristics 
to genotype in a cohort of consecutive patients diagnosed with HCM, due to the three known South 
African HCM-founder alleles (A797TMYH7; R403WMHY7; and R92WTNNT2) at Tygerberg Hospital in 
Cape Town, South Africa. CMR imaging was carried out at Groote Schuur Hospital, Cape Town, 
South Africa. 
 
8.2.2. Study population and definitions 
151 HCM mutation carriers (MCs) were successfully enrolled into the study. Seven patients had 
incomplete CMR studies. Another 11 patients had non-diagnostic CMR studies either due to 
presence of motion artefacts, mistriggering consequent to arrhythmias, or suboptimal late 
gadolinium enhancement (LGE) imaging. Two MCs had CMR evidence of dilated cardiomyopathy, 
and were subsequently also excluded from the analysis (Figure 8.1). 131 HCM MCs were included 
in the analysis (mean age 39.83 ± 16.2 years; 58% male). A sensitivity analysis indicated that the 
demographic profile of the 20 patients excluded from the analysis was similar to that of the 131 
patients analysed, and thus unlikely to have biased the analysis.  
 
The diagnosis of HCM was based on the presence of a hypertrophied (maximum end-diastolic wall 
thickness ≥ 14mm), non-dilated LV in the absence of other diseases capable of producing the 
degree of observed hypertrophy. Arterial hypertension was defined as a blood pressure greater than 
140/90 mmHg. Obesity was defined as a body mass index greater than 30 kg/m2. 
 
8.2.3. CMR measurements and data collection 
Subjects were scanned in a 1.5T MRI scanner (Symphony, Siemens Medical Systems, Erlangen, 
Germany) using a cardiac phased array coil. Initially, scout images were acquired with 2- and 4-
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chamber views, and were used to prescribe short-axis planes from base to apex for cine imaging. 
Imaging with steady-state free precession (SSFP), with segmented acquisition of k-space lines, was 
applied for cine imaging, with breath-holding by the patient for ± 6-10 seconds (~15 cardiac cycle 
lengths). The LV systolic function and mass were imaged with cine MRI along contiguous short-
axis slices (typically 1.4x1.4 mm/pixel and 7 mm slice thickness, with a 3 mm slice gap). The 
sequence parameters were as follows: repetition time (TR) 35 ms; echo time (TE) 1.5 ms; receiver 
bandwidth 930Hz/pixel; 256 readout points with oversampling; 165 phase encodings; 65º flip 
angle; a field of view with dimensions of 256mm in the phase encoding direction and 340mm in the 
read-out direction; and ≥15 phases per R-R interval. LGE imaging was performed with an inversion 
recovery method, after a dose of 0.2 mmol/kg of gadolinium-DTPA (gadodiamide, Omniscan®, 
General Electric Healthcare) with the inversion time optimized iteratively to maximally null the 
myocardium. 
 
8.2.4. CMR data analysis 
i. LV structure and function 
Cine CMR images were analysed offline with a validated image-processing software package 
(ARGUS; Siemens Medical Systems, Erlangen, Germany). End-diastolic and end-systolic images 
were identified with electrocardiographic (ECG) R-wave gating, and LV volume assessment. 
Contours of the endocardial and epicardial borders were manually delineated by two experienced 
observers, who were blinded to the genotypic information, from base to apex in end-diastole. Only 
endocardial contours were drawn in end-systole. LV end-systolic (LVESV) and end-diastolic 
(LVEDV) volumes were used to calculate stroke volume (SV) and ejection fraction (EF) – (EF = 
SV/EDV). Myocardial mass was calculated by subtracting the endocardial volume from the 
epicardial volume, based on prior knowledge of myocardial specific gravity (1.05 g/cm3). Left 
atrial diameter was measured in the LV outflow tract (3-chamber) view. 
ii. Late gadolinium enhancement 
Images were evaluated in a blinded fashion, for the presence or absence, pattern (focal, confluent or 
mixed), amount and regional distribution of LGE areas by a two observers with greater than 4 years 
of CMR experience. 
 
8.2.5. Ethical considerations 
The study was designed in keeping with the principles of the Helsinki Declaration. The study was 
approved by the Human Research Ethics Committees of Stellenbosch University and the University 
of Cape Town. All participants gave informed, written consent to participate in the study. 
 
8.2.6. Statistical analysis 
Normality of data was tested using the Kolmogorov-Smirnov test. Normally distributed data are 
presented as mean ± standard deviation (SD) or, where highly skewed, as median (interquartile 
range - IQR); categorical data are presented as numbers (percentages). The chi-square test or 
Fischer’s exact test was used to compare dichotomous data. The unpaired Student t-test (when 
normally distributed) or Mann- Whitney U test (for non-parametric data) was used to compare 
continuous variables. Bivariate correlations were assessed using the Pearson’s (R) or the 
Spearman’s (Rs) coefficient, as appropriate. Regression analysis used to determine relationship 
between LVH and LGE. All statistical tests were two-tailed and a p-value of less than 0.05 was 
considered statistically significant. All analysis was performed using SPSS version 20 (IBM, 
Armonk, New York, USA). 
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Figure 8.1. HCM patients enrolled into the study 
 
 
8.3 Results 
8.3.1. Baseline characteristics 
The demographic details of the HCM MCs included in the analysis are shown in Table 8.1. 
There were no differences in age, sex or co-morbid status when study participants were stratified by 
genotype. The prevalence of obesity and hypertension were low, likely reflecting the relatively 
young age of the study participants. 
 
Table 8.1. Baseline characteristics of HCM patients stratified by genotype 
 
A797TMYH7, the A797T mutation in the beta-myosin heavy chain gene; R403WMYH7, the 
R403W mutation in the beta-myosin heavy chain gene; R92WTNNT2, the R92W mutation in 
the cardiac troponin T gene; BP, blood pressure; BMI, body mass index 
 
8.3.2. CMR findings: LV structure and function 
Global systolic function was normal in all 3 HCM groups studied, as shown in Table 8.2. While 
within normal limits, there was a small but statistically significant increase in LVEF of R92WTNNT2 
MCs when compared to A797TMYH7 and R403WMYH7 MCs, (73.4 ± 6.3 vs. 67.2 ± 6.9 and 70.7 ± 
6.9, respectively) p=0.013. The R403WMYH7 MCs had greater frequency of inferior wall LVH 
compared to A797TMYH7 and R92WTNNT2 MCs, with maximal LVH occurring in the interventricular 
septum (p=0.043). There were also differences noted in the pattern of LVH between participants 
with different mutations. For instance, the R92WTNNT2 MCs had higher frequency of combined 
septal and apical hypertrophy; the A797TMYH7 MCs had more cases of isolated apical HCM; and the 
R403WMYH7 MCs had greater prevalence of asymmetric septal hypertrophy (p=0.006). Examples of 
patterns of LVH in HCM are depicted in Figure 8.2. There were no differences in the prevalence of 
left ventricular outflow tract (LVOT) obstruction between the different genotypes (p=0133). Also, 
there were no differences in left atrial (LA) size between the different groups (p=0.881). 
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8.3.3. CMR findings: regional fibrosis assessed by LGE 
The presence of LGE, assessed qualitatively, was higher in R403WMYH7 MCs compared to 
A797TMYH7 and R92WTNNT2 MCs (p=0.023), shown in Table 8.2. Focal LGE was found more 
commonly in A797TMYH7 and R403WMYH7 MCs, while the R92WTNNT2 MCs commonly had 
confluent or mixed patterns of LGE (p=0.001), Figure 8.3. 
 
8.3.4. Genotype correlations with CMR covariates of IVS thickness and LGE 
In A797TMYH7 MCs, interventricular septal (IVS) thickness correlated with male sex (RS 
0.333; p=0.011), left ventricular end-diastolic volume [LVEDV] (RS -0.638; p<0.001), LV 
mass (RS 0.642; p<0.001), LA size (RS 0.602; p<0.001), LVOT obstruction (RS 0.509; 
p<0.001), LGE presence (RS 0.756; p<0.001) and presence of mitral regurgitation (RS 0.411; 
p=0.001), as depicted in Table 8.3. In R403WMYH7 MCs, IVS thickness was found to correlate 
with age (RS 0.511; p=0.004), LVEDV (RS -0.393; p=0.032), LV mass (RS 0.503; p=0.005) 
and LGE presence (RS 0.363; p=0.049). In R92WTNNT2 MCs, IVS thickness correlated with 
age (RS 0.563; p<0.001), LVEDV (RS -0.461; p=0.002), LV mass (RS 0.571; p<0.001), LA 
size (RS 0.591; p=0.001), LVOT obstruction (RS 0.330; p=0.031), LGE presence (RS 0.656; 
p<0.001) and presence of mitral regurgitation (RS 0.538; p<0.001). 
 
In A797TMYH7 MCs, presence of LGE correlated with age (RS 0.281; p=0.033), LVEDV (RS - 
0.551; p<0.001), LV mass (RS 0.373; p=0.004), IVS thickness (RS 0.756; p<0.001), LA size 
(RS 0.557; p<0.001) and presence of mitral regurgitation (RS 0.359; p=0.006), shown in 
Table 8.4. In R403WMYH7 MCs, presence of LGE correlated with LA size (RS 0.393; p=0.032) 
and IVS thickness (RS 0.363; p=0.049). In R92WTNNT2 MCs, LGE presence correlated with 
LVEDV (RS -0.323; p=0.035), LA size (RS 0.379; p=0.012) and IVS thickness (RS 0.656; 
p<0.001).
 Table 8.2. CMR findings in HCM patients stratified by genotype 
 
 
LVEDV, left ventricular end-diastolic volume; BSA, body surface area; LVEF, left ventricular 
ejection fraction; LA, left atrium; IVS, interventricular septum; LVOT, left ventricular outflow tract 
obstruction; MR, mitral regurgitation; RV, right ventricle; LGE, late gadolinium enhancement 
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Figure 8.2. Patterns of LV hypertrophy found in HCM, demonstrated in short-axis images in 
end-diastole 
A, HCM with focal basal septum and/or anterior bulge; B, mid-ventricular asymmetrical septal left 
ventricular hypertrophy (including mid-cavitary HCM); C, apical HCM (short-axis apical diastolic 
slice showing apical hypertrophy); D, HCM with concentric left ventricular hypertrophy; E, mass-
like HCM (in this case, showing focal thickening in the anterior myocardium); F, HCM with non-
contiguous areas of left ventricular hypertrophy (including septal and inferior wall LVH, septal and 
apical LVH, or septal and lateral wall LVH); G, burnt-out HCM (with thinned and fibrotic 
myocardium and decreased LV systolic function); and H, genotype positive, phenotype negative 
HCM (with a normal CMR appearance) 
 
 
Figure 8.3. Patterns of LGE in HCM 
A, LGE in a healthy control; B, HCM patient with focal enhancement (shown in red arrows) in the 
superior and inferior LV/RV junctions; C, HCM patient with confluent (diffuse and patchy) 
enhancement throughout the myocardium (indicated in yellow arrows); D, HCM patient showing a 
mixed pattern of enhancement with focal enhancement in the hypertrophied septum (red arrow) an 
confluent mid-wall enhancement in the inferolateral wall; and E, another HCM patient with a mixed 
pattern, with a small area of focal fibrosis (red arrow) in the anterior wall and mostly confluent 
fibrosis (yellow arrow) in the inferolateral wall and septum 
 
 Table 8.3. Genotype correlations with CMR covariates of interventricular septal 
thickness 
 
 
RS, Spearman bivariate correlation; LV, left ventricle; LVEDV, left ventricular end-diastolic 
volume; LA, left atrium; LVOT, left ventricular outflow tract; LGE, late gadolinium enhancement; 
MR, mitral regurgitation 
 
Table 8.4. Genotype correlations with CMR covariates of LGE 
 
RS, Spearman bivariate correlation; LV, left ventricle; LVEDV, left ventricular end-diastolic 
volume; LA, left atrium; LVOT, left ventricular outflow tract; LGE late gadolinium 
enhancement; MR, mitral regurgitation 
 
8.3.5. Predictors of LGE presence in HCM 
On multivariate logistic regression analysis, LV mass was the only independent predictor of 
LGE (OR 1.73 [1.35 – 8.08]; p=0.035), as shown in Table 8.5. 
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Table 8.5. Logistic regression analysis of predictors of LGE in HCM 
 
LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular 
ejection fraction; LA, left atrium 
 
 
8.4 Discussion 
The key findings of the first detailed report on the CMR phenotype in a cohort of HCM mutation 
carriers with the three known South African HCM-founder alleles were: (i) global systolic function 
was within the normal range in all 3 groups, however, the R92WTNNT2 MCs had increased LVEF in 
comparison to A797TMYH7 and R403WMYH7 MCs; (ii) R403WMYH7 MCs had greater frequency of 
inferior wall and basal septal LVH and there were different patterns of LVH observed in MCs with 
different genotypes; (iii) LGE was more common in R403WMYH7 MCs, with focal LGE more 
prevalent in A797TMYH7 and R403WMYH7 MCs, and R92WTNNT2 MCs more frequently having 
confluent or mixed patterns of LGE; (iv) unique CMR covariates were found to correlate differently 
with genotype; and (v) LV mass was the only independent predictor of LGE presence, with an odds 
ratio of 1.73. This study contributes to our evolving understanding of genetic influence on 
phenotypic expression in HCM patients with the three unique South African HCM-founder 
mutations and suggests that CMR may be a useful tool in distinguishing variable phenotypic 
expression in HCM MCs with differing genotypes. 
 
On echocardiography, in South African HCM founder MCs with apparently mild disease, there was 
a positive correlation between age and IVS thickness for both the R403WMYH7 and R92WTNNT2 
mutations.193 In the same study, the period between development of LVH coincided with the years 
in which most SCD events occurred in male R92WTNNT2 MCs.193 We also demonstrate that in all 3 
groups of South African HCM mutations, IVS thickness correlated negatively with LVEDV and 
positively with LV mass and presence of LGE. Similarly, we also find a positive correlation 
between age and IVS thickness in R403WMYH7 and R92WTNNT2 MCs. In the A797TMYH7 and 
R403WMYH7 MCs, there was a correlation between IVS thickness and increasing LA size. 
Furthermore, in the A797TMYH7 and R92WTNNT2 MCs, IVS thickness correlated with presence of 
LVOT obstruction and mitral regurgitation. Greater CMR-defined LV mass and IVS thickness are 
associated with less favourable clinical outcome, likely reflecting the strong association of LVH 
with LVOT obstruction, SCD and advanced heart failure.194,195 
 
Regional myocardial fibrosis or scarring detected by LGE on CMR occurs in approximately 60% 
(range 30-90%) of HCM patients.195-197 While there are no LGE characteristics that are specific for 
HCM,198 the prognostic significance of LGE in HCM is high, as LGE is often associated with SCD, 
systolic dysfunction, and non-sustained ventricular tachycardia.199-202 We show that in all 3 groups 
of South African HCM mutations, LGE correlated with LA size and IVS thickness. In the 
A797TMYH7 and R92WTNNT2 MCs, LGE also correlated with age and LVEDV. The relationship of 
LGE to LVEF remains controversial, as some investigators have found no relationship,203 while 
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others have shown that percent of LV involvement by LGE inversely correlates with LVEF.204,205 In 
this study, most patients has a normal ejection fraction. However, it is important to note that the 
degree of fibrosis in HCM has not been shown to be a predictor of major cardiovascular events on 
multivariate analysis,202 likely due to small numbers of study subjects with events, and larger, 
multi-centre longitudinal studies are on-going for this assessment. 
 
On multivariate analysis, we show that presence of LGE is associated with LV mass. Similarly, a 
significant but modest relationship has been demonstrated between LVH and increased LV mass 
and LGE.204 Patients with LGE have greater LV mass index than patients without LGE. 201,205 
Furthermore, on an individual level, a relationship is evident between segmental LV wall thickness 
and LGE.204,205 Another comparison of echocardiographic structural and functional parameters 
between prehypertrophic South African MCs and non-MC family members revealed that (1) the 
R92WTNNT2 mutation correlated with a relative increase in systolic functional parameters; (2) the 
A797TMYH7 mutation correlated with reduced diastolic dysfunction; and (3) the R403WMYH7 
mutation correlated with both impaired systolic and diastolic dysfunction.206 In this study, overall 
systolic function was normal in all 3 genotypic groups. However, we also found that R92WTNNT2 
MCs had a relative increase in global systolic function when compared with A797TMYH7 and 
R403WMYH7 MCs. 
 
Our sub-study has several limitations. First, while there are several structural and functional 
genotypic correlates noted, there is significant overlap between these phenotypes. Second, the 
presence of correlation does not equate to causation. Nevertheless, the study was not designed to 
assess for causal links between genotype and phenotype. Third, it would have been interesting to 
assess the relationship of the CMR parameters with clinical outcomes in this unique cohort of HCM 
MCs, though this was not the purpose of this study. However despite these limitations, we 
succeeded in achieving our primary objective of investigating genotype: phenotype correlations in 
HCM MCs due the South Africa founder alleles. 
 
8.5 Conclusions 
In this comprehensive report on genotype correlations with CMR phenotype, in a cohort of HCM 
MCs with the three known South African HCM-founder alleles, we show differences in pattern of 
LVH, and in frequency and pattern of LGE when comparing different genotypes. Furthermore, we 
also show that presence of LGE is related to LV mass index. Moreover, this study suggests that 
CMR is capable of distinguishing variable phenotypic expression in HCM MCs with differing 
genotypes, and contributes to our evolving understanding of the genetic influence on phenotypic 
expression in HCM patients with the three unique South African HCM-founder mutations.  
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Chapter 9 
 
 
Conclusions 
 
 
 
While little is known about the mechanisms, clinical characteristics, natural history and outcomes of 
cardiomyopathy amongst Africans, this series of studies aimed to broaden our understanding of 
cardiomyopathies among Africans and to investigate the clinical features and outcomes of both 
familial and non-familial cardiomyopathies. We hypothesise that cardiomyopathies are a caused by 
familial/genetic and non-familial/non-genetic factors, and that disease onset, clinical and 
pathological features, disease progression and severity, and disease prognosis vary based on 
familial/genetic and non-familial/non-genetic aetiology.. It is our belief that the series of sub-studies 
discussed above, indeed support this hypothesis. A major limitation of this work is that molecular 
genetics were not available for all cardiomyopathy patients studied at the completion of this thesis. 
However, these analyses are ongoing, and it is our belief that they will provide further evidence to 
support our contention of genetic underpinnings of cardiomyopathy. 
 
The sarcomere has long been recognised as the principal contractile unit of striated muscle. A 
recent publication has supported our hypothesis, showing that mutations in genes encoding 
sarcomeric proteins are responsible for a range of diseases including hypertrophic, dilated and 
restrictive cardiomyopathies and ventricular non-compaction.207 The authors critically appraise the 
evidence in this area and conclude that the downstream molecular pathways leading to these 
heterogeneous phenotypes include changes in acto-myosin cross-bridge kinetics, altered 
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mechanosensation, disturbed calcium sensitivity, deregulated signalling pathways, inefficient 
myocardial energetics, myocardial ischaemia and myocardial fibrosis.208-212 Elucidation of the 
genetic causes of cardiomyopathy has helped in understanding the structure and function of the 
sarcomere and a more detailed knowledge of the sarcomere and its associated proteins has 
suggested additional gene candidates.  
 
 
Figure 9.1. Schematic showing that sarcomeric mutations can lead to variable phenotypic 
expression in the cardiomyopathies 
From Lopes LR, Elliott PM. A straightforward guide to the sarcomeric basis of cardiomyopathies. 
Heart 2014;100:1916-1923. 
 
 Table 9.1. Summary of the sarcomeric and associated proteins, encoded genes, interactions, 
associated disease phenotypes and respective prevalence 
 
From Lopes LR, Elliott PM. A straightforward guide to the sarcomeric basis of cardiomyopathies. 
Heart 2014;100:1916-1923. 
 
In this study, two cohorts of patients with cardiomyopathy were utilised: (1) patients with 
cardiomyopathy seen at the specialist cardiomyopathy clinic at GSH, Cape Town between February 
1, 1996 and December 31, 2009; and (2) a group of HCM patients and first degree relatives seen in 
a specialist cardiogenetic clinic at Tygerberg Hospital, who underwent CMR at GSH. 
 
29 out of 109 unrelated cases with DCM had familial disease, and had a significantly younger mean 
age of onset of cardiomyopathy than non-familial cases. Two of the 29 patients with familial DCM 
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had at least one relative who was diagnosed with PPCM. Pedigree analysis of the 29 families was 
consistent with AD inheritance in 72.4%, AR inheritance in 17.2% and X-LR inheritance in 10.4%. 
Cardiac chambers were significantly more dilated with poorer LV systolic function in idiopathic 
than familial cases. The mortality rate of 40% after a median follow-up of 5 years was, however, 
similar in both groups. The presence of New York Heart Association functional class III and IV 
symptoms was an independent predictor of mortality, whilst heart transplantation was an 
independent predictor of survival in both groups. Digoxin use without serum monitoring was a 
significant predictor of mortality in idiopathic DCM.  
 
We also presented the longest follow-up study of PPCM in Africans, showing (1) a case fatality rate 
of 16.7% over a median of 4.3 years in patients on modern medical therapy; (2) PPCM is associated 
with adverse outcomes; (3) chronic heart failure occurs in 80% of patients studied, and with 
virtually no normalisation of LV dysfunction; and (4) that persistence of symptoms of heart failure 
are the strongest predictor of death in patients with PPCM. We compared the time of onset of 
symptoms, clinical profile and outcome of patients with HHFP and PPCM and found onset of 
symptoms to be postpartum in all PPCM patients and antepartum in 85% of HHFP. PPCM was 
associated with more severe complications and a higher rate of mortality.   
 
Clinical presentation of HCM in South Africa was similar to that reported in other studies from 
other parts of the world. The South African founder mutations that cause HCM were not found in 
the 42 probands studied at GSH and 29% of those tested for mutations in 15 genes had disease 
causing mutations in MYH7 and MYBPC3. Overall survival of HCM was 74% at 10 years, which 
was similar to the general South African population. The independent predictor of mortality was the 
presence of multiple genetic variants with or without a disease-causing mutation in any of the 15 
genes tested. Finally, we investigated the correlation between genotype and CMR phenotype in 
HCM patients with the 3 founder South African mutations and found variable phenotypic 
expression associated with the different genotypes.  
 
Indeed, the studies in this thesis have contributed to our evolving understanding of the complex 
disease concepts of pathophysiology, clinical presentation, natural history and outcomes in various 
cardiomyopathies in Africans. Future studies are needed to test the hypothesis that 
cardiomyopathies represent a continuum of the same disease spectrum with identical genetic 
abnormalities and disease onset, clinical and pathological features, disease progression and severity, 
and disease prognosis that is variable and is modulated by different host and environmental factors. 
In the future, larger, multicentre studies of the molecular genetic underpinnings of cardiomyopathy 
among Africans should lend greater support to this hypothesis.
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